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Background: Retained placenta is associated with postpartum haemorrhage and can lead to significant
maternal morbidity if untreated. The only effective treatment is the surgical procedure of manual removal
of placenta, which is costly, requires skilled staff, requires an operative environment and is unpleasant for
women. Small studies suggest that glyceryl trinitrate may be an effective medical alternative.
Objective: To determine the clinical effectiveness and cost-effectiveness of sublingual glyceryl trinitrate
spray compared with placebo in reducing the need for manual removal of placenta in women with
retained placenta after vaginal delivery following the failure of current management.
Design: A group-sequential randomised double-blind placebo-controlled trial with a cost-effectiveness
analysis.
Setting: There were 29 obstetric units in the UK involved in the study.
Participants: There were 1107 women (glyceryl trinitrate group, n = 543; placebo group, n = 564)
randomised between October 2014 and July 2017.
Interventions: Glyceryl trinitrate spray was administered to 541 women in the intervention group, and a
placebo was administered to 563 women in the control group.
Main outcome measures: Four primary outcomes were defined: (1) clinical – the need for manual
removal of placenta, (2) safety – measured blood loss, (3) patient sided – satisfaction with treatment and
side effects and (4) economic – cost-effectiveness of both treatments using the UK NHS perspective.
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Secondary clinical outcomes included a > 15% decrease in haemoglobin level, time from randomisation
to delivery of placenta in theatre, the need for earlier manual removal of placenta than planned, increase
in heart rate or decrease in blood pressure, requirement for blood transfusion, requirement for general
anaesthesia, maternal pyrexia, and sustained uterine relaxation requiring additional uterotonics.
Results: No difference was observed between the glyceryl trinitrate group and the control group for the
placenta remaining undelivered within 15 minutes of study treatment (93.3% vs. 92%; odds ratio 1.01,
95% confidence interval 0.98 to 1.04; p = 0.393). There was no difference in blood loss of > 1000ml between
the glyceryl trinitrate group and the control group (22.2% vs. 15.5%; odds ratio 1.14, 95% confidence
interval 0.88 to 1.48; p = 0.314). Palpitations were more common in the glyceryl trinitrate group than in the
control group after taking the study drug (9.8% vs. 4.0%; odds ratio 2.60, 95% confidence interval 1.40 to
4.84; p = 0.003). There was no difference in any other measures of patient satisfaction between the groups.
There was no difference in costs to the health service between groups (mean difference £55.30, 95% confidence
interval –£199.20 to £309.79). Secondary outcomes revealed that a fall in systolic or diastolic blood pressure, or
an increase in heart rate, was more common in the glyceryl trinitrate group than in the control group (odds ratio
4.9, 95% confidence interval 3.7 to 6.4; p < 0.001). The need for a blood transfusion was also more
common in the glyceryl trinitrate group than in the control group (odds ratio 1.53, 95% confidence interval
1.04 to 2.25; p = 0.033).
Conclusions: Glyceryl trinitrate spray did not increase the delivery of retained placenta within 15 minutes of
administration when compared with the placebo, and was not cost-effective for medical management of
retained placenta. More participants reported palpitations and required a blood transfusion in the glyceryl
trinitrate group. Further research into alternative methods of medical management of retained placenta is
required.
Trial registration: Current Controlled Trials ISRCTN88609453.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 70.
See the NIHR Journals Library website for further project information.
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Plain English summary
A retained placenta is diagnosed when, following the birth of a baby, the placenta is not delivered.When this situation occurs, women are at risk of bleeding heavily. The only way to treat a retained
placenta is for a trained doctor to remove it by an operation in theatre. This procedure can be painful and
upsetting. Furthermore, the timing of the operation can interrupt mother–baby bonding immediately after
giving birth.
The study tested if the use of glyceryl trinitrate spray, given as two puffs under the woman’s tongue
following the diagnosis of retained placenta, may help the placenta to deliver without an operation.
The study also tested if glyceryl trinitrate was safe, assessed what women thought about the treatment
and compared the costs of glyceryl trinitrate with those of current operative management.
This study included 1107 women diagnosed with retained placenta following the birth of their baby.
Half of the women were treated with glyceryl trinitrate spray and the other half were treated with a
dummy spray, which looked identical but did not contain the active treatment. If the placenta delivered
within 15 minutes of the study treatment being taken, this was considered a success. However, if the
placenta did not deliver within 15 minutes and the woman had to have her placenta removed by an
operation, then this was viewed as unsuccessful. Neither the woman nor the clinical staff knew if the
treatment given was the glyceryl trinitrate spray or the dummy spray.
The results indicate that, although women were happy to be involved in the trial and the treatment was
safe, the use of glyceryl trinitrate spray did not reduce the need for the placenta to be manually removed
by an operation in theatre. Furthermore, glyceryl trinitrate spray was not cost-effective.
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Scientific summary
Background
Retained placenta following childbirth is a major cause of postpartum haemorrhage, which can ultimately
lead to maternal death. The diagnosis is made when the placenta fails to deliver with 30 minutes of
active management, or 60 minutes of physiological treatment followed by 30 minutes of active treatment.
Women are at greater risk of having a retained placenta if they have previously experienced one in prior
childbirth, are aged > 30 years or have a preterm birth or stillbirth. Retained placenta affects approximately
2% of vaginal deliveries, which is approximately 11,000 women in the UK per annum. Major obstetric
haemorrhage affects nearly 1 in 180 women and is the most common cause of maternal morbidity.
The current treatment for retained placenta is by a surgical procedure during which the placenta is removed
manually by an obstetrician. A hand is inserted into the vagina and the placenta is removed from the uterus.
This procedure normally involves transfer of the woman to an operating theatre where it is performed under
general, spinal or epidural anaesthesia. Manual removal of placenta is, therefore, a costly procedure in terms
of the number of hospital staff that are required. In addition, it can be very stressful for a woman to be
separated from her newborn child to undergo the procedure of manual removal of placenta.
Previous studies have suggested that use of a nitric oxide donor may be effective in helping an adherent
placenta to be removed from the uterine wall. This is thought to be effective because the nitrate induces
relaxation of uterine smooth muscle, thereby allowing the placenta to detach from the uterus. A few small
studies have been undertaken involving the use of intravenous glyceryl trinitrate for women who have
sustained a retained placenta, as well as using a tablet form of this preparation. Giving glyceryl trinitrate
to women to facilitate placenta removal has been reported with varying amounts of success. In addition,
small non-randomised or underpowered trials have suggested that administering glyceryl trinitrate sublingually
may be a more effective way of aiding placenta removal than the intravenous or tablet preparations. Sublingual
glyceryl trinitrate also has a benefit of being more stable at room temperature than either the intravenous form
or the tablet form. However, to our knowledge, no large-scale randomised double-blind case-controlled clinical
trial of sublingual glyceryl trinitrate for medical management of retained placenta had been undertaken.
Objectives
To determine the clinical effectiveness and cost-effectiveness of sublingual glyceryl trinitrate spray
compared with placebo in reducing the need for the manual removal of retained placenta in women
after vaginal delivery following the failure of current management.
Methods
The Glyceryl trinitrate fOr reTaIned placenTa (GOT-IT) study was designed as a multicentre randomised
controlled trial, with a nested qualitative pilot study and a health economic analysis. All necessary approvals
were sought and ethics approval was obtained from the North East – Newcastle and North Tyneside 2
Research Ethics Committee (reference number 13/NE/0339). The study was conducted in 29 obstetric sites
in the UK, and the aim was to recruit 1086 women to give the study 90% power with a 5% level of
significance. Women in a labour ward setting were considered for the trial if they were diagnosed with a
retained placenta, were aged ≥ 16 years, had delivered vaginally, were at > 14 weeks’ gestation and were
haemodynamically stable. Women were excluded if they were unable to give informed consent, had
suspected placenta accreta/increta/percreta or had a multiple pregnancy and had undergone an
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instrumental delivery in theatre. We also excluded women who had a known allergy to any constituent
of the study medication, had consumed alcohol in the last 24 hours or were currently taking
phosphodiesterase inhibitors. Finally, we also excluded women who were known to have other serious
conditions (e.g. if they were anaemic or cardiovascularly compromised). Only a clinician could confirm that
a potential participant was eligible to be consented to the trial.
Clinicians or midwives who were trained in obtaining informed consent and in study procedures approached
women who were considered to be eligible for the trial. Women who were willing to participate could
provide either verbal or written consent. If verbal consent was obtained, then written consent was collected
as soon as the woman was well enough to provide it. Following the consenting procedure, women were
then randomised by a ‘next pack off the shelf’ method to either the glyceryl trinitrate group or the placebo
group. Neither the women nor the labour ward staff were aware of which treatment the women were
randomised to because both the study medication and the placebo were packaged identically. Before
receiving the study medication, women had a baseline set of clinical observations taken that included
measurements of heart rate, blood pressure and temperature. If these were within the correct parameters,
women would self-administer the study treatment via a pump-primed canister, which delivered 400 µg of
glyceryl trinitrate per metered spray. Two sprays were prescribed sublingually delivering a total dose of
800 µg. Women had their heart rate, systolic blood pressure and temperature recordings repeated at both
5 and 15 minutes following administration of the study treatment. A blood sample was collected to measure
haemoglobin level on the first postnatal day. Women were also asked to complete a short questionnaire prior
to hospital discharge and again at 6 weeks post discharge.
There were four primary outcomes: clinical, safety, patient sided and economic. The primary clinical
outcome was defined as the placenta remaining undelivered 15 minutes after administration of the study
treatment and/or delivery being required within 15 minutes of administration of the study treatment
because of safety concerns. The primary safety outcome was measured blood loss between administration
of the study treatment and transfer to another clinical area or the postnatal ward. The patient-sided
outcomes were measured by questionnaires and focused on side-effect profile and satisfaction with
treatment. The primary economic outcome was designed to establish if there were net incremental costs
(or cost savings) to the NHS using glyceryl trinitrate spray versus standard practice. The study was analysed
using an intention-to-treat basis, estimating the effect using odds ratios and 95% confidence intervals.
We designed the trial assuming a 50% control (placebo) rate (giving maximum binomial variability) and
a 10% absolute reduction in those needing manual removal of placenta (informed by consultation with
patients and expert clinicians).
The clinical secondary outcomes that were measured included:
l time from randomisation to the delivery of the placenta
l manual removal of placenta in theatre
l need for earlier than planned manual removal because of clinical concerns
l fall in haemoglobin level of > 15% between recruitment and the first postnatal day
l fall in either diastolic or systolic blood pressure of > 15 mmHg and/or increase in heart rate of
> 20 beats per minute (b.p.m.) between baseline and 5 and 15 minutes following administration
of study treatment
l requirement for blood transfusion between delivery and postnatal discharge from hospital
l requirement for general anaesthesia
l maternal pyrexia
l sustained uterine relaxation after the placenta has been removed needing treatment with uterotonics.
Economic secondary outcomes studied the mean costs by treatment allocation group and the incremental
cost associated with the use of glyceryl trinitrate was estimated using a specified general linear model.
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An economic analysis was performed where the primary economic outcome was the net incremental cost 
(or cost saving) to the NHS of using glyceryl trinitrate spray for the treatment of retained placenta.
Results
A total of 1671 women were screened from October 2014 until July 2017 from 29 participating UK 
hospitals. Of those 1671 women, 1188 were eligible. Among those 483 patients who were not eligible, 
353 were ineligible, 63 declined and 60 were missed, and it was thought not appropriate to recruit seven 
patients. Among those 1188 patients who were eligible, 63 women declined, 10 women delivered the 
placenta before there was an opportunity to gain consent and eight women became ineligible prior to 
consent. Therefore, 543 women were randomised to receive glyceryl trinitrate spray and 564 women were 
randomised to receive the placebo. There were three postrandomisation exclusions (two in the glyceryl 
trinitrate group and one in the placebo group) attributable to a violation of baseline observations.
There was no difference in the primary clinical outcome between groups (odds ratio 1.01, 95% confidence 
interval 0.98 to 1.04; p = 0.393). There was no difference in the primary safety outcome of blood loss
> 1000 ml between administration of the study drug and transfer to the postnatal ward or other clinical
area (odds ratio 1.14, 95% confidence interval 0.88 to 1.48; p = 0.314).
The only difference in the patient satisfaction and side-effect profile between the two groups was in the
reporting of palpitations/heart racing in the pre-discharge questionnaire. Women in the glyceryl trinitrate
group reported significantly more episodes of palpitations and heart racing than those who had received
the placebo: 36 (9.8%) in the glyceryl trinitrate group and 15 (4.0%) in the placebo group (odds ratio 2.60,
95% confidence interval 1.40 to 4.84; p = 0.003).
There were some differences observed between the two groups in terms of secondary outcomes. More
women in the glyceryl trinitrate group demonstrated a drop of 15 mmHg of systolic blood pressure or
diastolic blood pressure or an increase in heart rate of 20 b.p.m. between baseline and 15 minutes after
receiving the study drug (odds ratio 4.90, 95% confidence interval 3.73 to 6.42; p < 0.001). Blood
transfusion prior to hospital discharge was also more common in women receiving glyceryl trinitrate than
the placebo (odds ratio 1.53, 95% confidence interval 1.04 to 2.25; p = 0.033). There was no difference in
any of the other secondary outcomes between study groups. There was also no difference in costs to the
health service between groups (mean difference £55.30, 95% confidence interval –£199.20 to £309.79).
Conclusions
There was no evidence to suggest that the administration of the glyceryl trinitrate spray to women who
were diagnosed with a retained placenta reduced the need for manual removal of placenta. Glyceryl
trinitrate spray did not provide an alternative medical management for removal of retained placenta.
There was no difference observed in blood loss between the glyceryl trinitrate group and the placebo
group, and women who received the glyceryl trinitrate spray rather than the placebo were more likely to
report palpitations during their hospital admission. However, by 6 weeks this difference was no longer
observed between the two groups. A decrease in blood pressure or an increase in heart rate was
significantly more likely to be experienced by those women who received glyceryl trinitrate. This is
consistent with the vasodilatory properties of glyceryl trinitrate. Women who received glyceryl trinitrate
were more likely to have a blood transfusion than those who received placebo. Finally, the use of glyceryl
trinitrate for the treatment of retained placenta was not proven to be cost-effective when compared with
standard practice.
Future research is still required to identify suitable medical management of placenta removal as an
alternative to the standard care of surgical removal.
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Trial registration
The trial is registered with the International Standard Randomised Controlled Trial Number (ISRCTN)
registry as ISRCTN88609453.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research and will be published in full in Health Technology Assessment; Vol. 23, No. 70.
See the NIHR Journals Library website for further project information.
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Chapter 1 Introduction
Background and rationale
Retained placenta
A retained placenta is diagnosed when the placenta is not delivered within 30 minutes following active
management of the third stage of labour after delivery of the baby (comprising routine use of uterotonic
drugs, early clamping and cutting of the cord and controlled cord traction) or within 60 minutes following
physiological management of the third stage (no routine use of uterotonic drugs, no clamping of the cord
until pulsation has ceased and delivery of the placenta by maternal effort) followed by active management
as per the National Institute for Health and Care Excellence (NICE) Clinical Guideline 190.1 The incidence of
retained placenta is rising in the UK because of changes in maternal demographics, increased intrapartum
interventions and operations involving exploration of the uterine cavity (e.g. surgical termination of
pregnancy and dilatation and curettage).2 It affects 2% of vaginal deliveries,2 which equates to nearly
11,000 women in the UK per annum. Retained placenta is a major cause of postpartum haemorrhage,3,4
with major obstetric haemorrhage affecting nearly 1 in 180 women and being the most common cause
of significant maternal morbidity.5 Following the failure of active or physiological management, NICE
recommends that retained placenta should be treated by manual removal of placenta.1 Compared with
spontaneous placental delivery, this surgical procedure (which requires an operative environment and
trained personnel) has its own risks, including bleeding6 and infection.7 In addition, delays incurred
while arranging this operative procedure increases risk of significant haemorrhage.4 Furthermore, the
infrastructure required for this operative intervention is not available in all delivery settings and the invasive
nature of this procedure has the potential to delay or interrupt mother–baby bonding in the immediate
postpartum period. The Cochrane Group8 and NICE1 both recognise that non-surgical management
options for retained placenta are limited and have recommended that research is needed into new medical
strategies of retained placenta. New (and effective) treatments for retained placenta would dramatically
reduce the number of women requiring manual removal of placenta, with the operation being restricted to
the small minority of women with particularly adherent placentae (partial placenta accreta). The reduction
in operative interventions would have cost benefits for the NHS and also benefits for women in terms of
increased satisfaction, less separation of mother and baby immediately after birth and reduced morbidity.
Rationale
Rationale for glyceryl trinitrate (nitric oxide donor) for retained placenta
The first report of a nitric oxide donor being used as a treatment for retained placenta was in 1811 when
inhalation amyl nitrate was used to treat a uterine constriction ring, thus facilitating manual removal of
placenta.9 Since then, numerous observational studies have suggested that nitric oxide donors including
glyceryl trinitrate (GTN) might be effective for the management of retained placenta. Many of these studies
used intravenous boluses of GTN10 ranging from 50 µg to 200 µg, with uterine relaxation occurring about
60 seconds after injection and lasting for 2 minutes. Of the five observational studies that report the use
of intravenous GTN for management of retained placenta (50–200 µg, up to two doses; n = 87 women),
success rates range from 94% to 100%.11–14 In these small studies, intravenous GTN appears to be
efficacious for retained placenta; however, intravenous administration can cause problematic side effects,
including symptomatic hypotension, particularly when given at higher doses, and it is not possible to
administer GTN by this route in all settings.15
More recently, alternative formulations of sublingual GTN have been trialled. All studies have used sublingual
GTN at 1 mg. Two small studies16,17 (n = 48 women) suggested that GTN given as a sublingual tablet was
effective in treating retained placenta. However, a larger study [International Standard Randomised
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Controlled Trial Number (ISRCTN) 34755982; n = 105 women] showed no benefit of GTN over placebo
for treatment of retained placenta (37.3% vs. 20.4%; p > 0.05).16 Compared with the tablet preparation,
sublingual GTN spray18 has several advantages including stability at room temperature, significant reduction
in latency of onset (with onset beginning at 30–45 seconds, peaking at 90–120 seconds and lasting up to
5 minutes)19–21 and fewer problematic subjective and objective side effects.22 Anecdotal reports allude to GTN
spray having a potential utility in the medical treatment of retained placenta.18 GTN spray is used for other
obstetric emergencies when uterine relaxation is required, such as releasing a trapped head at caesarean
section or in breech delivery.18 Clinicians are therefore familiar with the use of sublingual GTN spray in the
emergency obstetric setting, which potentially lowers the barrier for trialling its use for retained placenta.
Biological plausibility of glyceryl trinitrate for the management of retained placenta
It is likely that failure of myometrial contractions, placental trapping and adherence to the myometrium
contribute variably to the ultimate clinical diagnosis of retained placenta. In placentae that are detached
but trapped behind a myometrial contraction ring, GTN could potentially treat retained placenta simply by
relaxing local uterine muscle constriction and, thereby, effecting placental release.8 For adherent placenta,
Farley et al.23 have suggested that nitric oxide-mediated contraction and relaxation of human chorionic
villi along their longitudinal axis might serve as a GTN-mediated mechanism for placental separation.
For placentae that are retained because of partial placenta accreta, currently available nitric oxide drugs
(including GTN) are unlikely to effect release and surgical management is likely to remain the preferred
method of treatment.
Conclusion
Although there is an increasing amount of evidence that supports the use of GTN for treatment of
retained placenta, much of this evidence is based on anecdotal case reports or clinical ‘trials’ that are
non-randomised, do not contain a placebo group and are underpowered.16,17 In addition, in the context of
constrained maternity resources in a publicly funded health system, it is important to quantify the costs
associated with GTN (including any subsequent monitoring costs and costs associated with complications)
in relation to its effectiveness and any subsequent cost savings it may deliver over standard practice.
There is therefore an urgent need for a pragmatic clinical trial of GTN for those with a retained placenta
to determine whether or not GTN is efficacious, safe, acceptable and cost-effective as a treatment for
retained placenta before a treatment, which may (or may not) work, is embedded within routine clinical
practice. In response to a Health Technology Assessment (HTA) commissioned call, we aimed to determine
whether or not sublingual GTN was clinically effective and cost-effective for the medical management of
retained placenta in a randomised placebo-controlled double-blind pragmatic UK-wide Glyceryl trinitrate
fOr reTaIned placenTa (GOT-IT) trial.
Objectives
The overall aim of the randomised placebo-controlled double-blind pragmatic UK-wide GOT-IT trial
(with internal pilot study) was to determine the clinical effectiveness and cost-effectiveness of sublingual
GTN spray compared with placebo in reducing the need for manual removal of placenta in women with
retained placenta after vaginal delivery following the failure of current management. Outcomes were
measured over four inter-related domains: clinical, safety, patient sided and economic.
The primary research objectives of the internal pilot randomised controlled trial (RCT) were as follows:
l to demonstrate trial processes for approaching women, gaining consent, randomising, treating and
assessing outcomes were optimal, and to implement improvements as required
l to determine achievable recruitment rates
l to determine the probable effect size, to inform calculation on whether or not the planned sample size
could be reduced while maintaining study power
l to pilot and modify if required the postpartum questionnaires (assessment of patient satisfaction and
collection of health service use outcomes).
INTRODUCTION
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The primary research objectives of the substantive GOT-IT RCT were as follows:
l to determine the clinical effectiveness of sublingual GTN in treating retained placenta and avoiding
manual removal of placenta in women with vaginal delivery following failure of current management
(defined as the third stage of labour lasting more than 30 minutes after active management or 60 minutes
after physiological management followed by active management respectively) (clinical domain)
l to determine the side-effect profile for GTN given to treat retained placenta (safety domain)
l to assess patient satisfaction with GTN given for retained placenta (patient-sided domain)
l to assess the net costs (or cost savings) to the NHS of using GTN for the treatment of retained placenta
compared with standard practice (economic domain).
The secondary objectives were to assess NHS costs in relation to the primary outcome and a range of
secondary outcomes expected to differ between the groups in the trial, using a cost–consequences balance
sheet approach.
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Chapter 2 Methods
Trial design
The GOT-IT trial was a multicentre, pragmatic group-sequential, placebo-controlled, randomised trial with
cost-effectiveness analysis. The study protocol can be accessed from www.journalslibrary.nihr.ac.uk/
programmes/hta/122901/#/ (accessed 31 May 2019).
Setting
The trial was conducted in the delivery suites of 29 hospitals with obstetric units in 27 NHS trusts and boards
in England and Scotland. The delivery wards were of varying size and location to ensure that the results of
the trial were generalisable to the UK. Women did not have to have delivered in obstetric units to be eligible
for trial entry: if a woman developed a retained placenta following failure of current management after
giving birth at home or at a stand-alone or along-side midwifery delivery unit, she was still eligible for trial
entry once admitted to one of the recruiting centres.
Participants
The trial was designed to include an internal pilot trial, which aimed to recruit 75 women from eight pilot
sites. Once recruited to the pilot trial, those women also formed part of the main substantive RCT. The
number of sites planned for the main substantive trial was a minimum of 20, and the final number of sites
included was 29. The number of participants required to be recruited into the main trial was informed by
the group-sequential design. If the trial recruited to maximum size, 1100 participants were required to be
recruited.
Eligibility criteria
Inclusion criteria
l Women with retained placenta.
l Women aged ≥ 16 years.
l Women with vaginal delivery in the incident pregnancy (including women with past obstetric history of
caesarean section in a previous pregnancy).
l Women who were haemodynamically stable, defined as having a systolic blood pressure level of
> 100 mmHg and a pulse of < 110 beats per minute (b.p.m.).
l Women who delivered at > 14 weeks’ gestation in the incident pregnancy.
Exclusion criteria
l Women who were unable to give informed consent.
l Women with suspected placenta accreta, increta or percreta in the incident pregnancy.
l Multiple pregnancy in the incident pregnancy.
l Women who had an instrumental vaginal delivery in the incident pregnancy.
l Women with an allergy or hypersensitivity to nitrates or to any other constituent of the formulation of
the study medication.
l Women who had taken alcohol in the 24 hours prior to delivery.
l Women with a history of phosphodiesterase inhibitor use during pregnancy.
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l Women with a contraindication to GTN administration because of one or more of the following:
incipient glaucoma, severe anaemia, profound bradycardia, glucose-6-phosphatedehyrogenase
deficiency, brain trauma and cerebral haemorrhage, angina, mitral and/or aortic stenosis caused by
hypertrophic obstructive cardiomyopathy, constrictive pericarditis, circulatory collapse due to cardiogenic
shock and toxic pulmonary oedema.
The trial was designed to be pragmatic, and the inclusion and exclusion criteria were therefore as broad
and as inclusive as possible. However, we decided to exclude women with multiple pregnancies and
women who were in theatre having an instrumental vaginal delivery for the following reasons:
l Measured blood loss between randomisation and transfer to the postnatal ward was our prespecified
primary safety outcome. Multiple pregnancy is an independent risk factor for haemorrhage and these
women were likely to have significantly higher blood loss than women with singleton pregnancies.
l If women were already in theatre having an instrumental delivery with adequate analgesia, we thought
that it would be highly unlikely that the obstetrician delivering the baby would wait for 30 minutes
after active management or 60 minutes after physiological management plus a further 30 minutes of
active management before diagnosing a retained placenta. In such an operative environment in which
skilled personnel and appropriate analgesia were already in place, the threshold to proceed to manual
removal of placenta would be much lower. Furthermore, our midwifery and lay representatives felt
strongly that in this situation it would be unethical and undignified for a woman to remain in theatre
for longer than required when the only reason to do so would be to fulfil eligibility criteria.
l If we had included these two groups we would have required to stratify the data and significantly
increase the sample size, which may have made the trial unfeasible.
Co-enrolment
Participation in another clinical trial of an investigational medicinal product (CTIMP) was initially an exclusion
criterion. However, as enrolment to the GOT-IT trial could occur only once the diagnosis of retained
placenta had been made, many women who would otherwise have been eligible were being ruled out
as they were already participating in another CTIMP. We therefore submitted a substantial amendment
that permitted co-enrolment between CTIMP studies providing there was a CTIMP-to-CTIMP agreement.
This involved proposals for co-enrolment between CTIMP studies to be captured in a written, authorised
agreement between the sponsors and chief investigators of each study.
Recruitment procedure
Recruitment was initiated on 13 October 2014 and completed by 26 July 2017 in the delivery wards of 29
UK maternity hospitals.
Screening and consent
Clinicians undertook the initial eligibility screening. Women were identified as being potentially eligible for
the trial if, following vaginal birth, they had a retained placenta and were at risk of needing a manual removal
of placenta after failure of current management of the third stage of labour, defined as the placenta remaining
undelivered after (1) 30 minutes of active management or (2) 60 minutes of physiological management
followed by 30 minutes of active management.
Following the diagnosis of a retained placenta and successful screening, women were approached by
either a clinician or a midwife who had received the approved GOT-IT training package that had sponsor-
approved good clinical practice training embedded within it. Potential participants were given verbal and
written information about the trial, with the latter consisting of a summary and a full patient information
sheet. Women were given an opportunity to ask questions relating to any aspect of the trial in order to
gain a full understanding of what was required of them. The patient information leaflets contained
information that explained that sublingual GTN was being investigated as a possible treatment for retained
METHODS
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placenta. If women wished to participate then verbal or written consent was obtained. If consent was
gained verbally, written consent had to be taken as soon as possible after the trial. This approach has been
endorsed by the Royal College of Obstetricians and Gynaecologists in recent guidance about obtaining
consent in perinatal research where consent time is critical.24
Written consent involved obtaining a dated signature from the participant and a dated signature from the
consenter. The consent form included a clear explanation that the woman could withdraw from the trial at
any time without providing a reason if she wished, and that if she chose to do so it would not influence
any future medical care. A copy of the signed informed consent form was returned to the woman, another
copy filed in her medical notes and the original was obtained in the investigator site file.
Consent and recruitment of subjects undertaken in the qualitative pilot trial25–27 led us to improve the
consent and recruitment procedure for those subjects recruited to the substantive trial (see Chapter 3 for
further details and www.journalslibrary.nihr.ac.uk/programmes/hta/122901/#/). In response to feedback
from women, information, with researcher contact details, was provided to women antenatally, if they
were thought to be at a high risk of having a retained placenta, for example a history of previous retained
placenta.28 This is an example of how the qualitative trial strengthened the substantive trial.
Randomisation, concealment and blinding
Study medication was provided to site pharmacies in pre-packed randomised permuted blocks. Drug packs
were ordered from the pharmacy and stored in the labour ward setting. Eligible participants were randomly
assigned to active treatment with GTN or an identical-looking placebo.
The method of randomisation was via the next available treatment pack from the shelf. The drug pack
number on the pack and the vial was recorded in the women’s medical notes, in study documentation
and entered into the electronic database. Subjects were randomised in a 1 : 1 ratio of GTN to placebo.
Study staff advised the women on how to deliver the study medication and provided, prior to drug
administration, a leaflet demonstrating its use.
As the design of the study was double blind, neither the women nor the onsite study staff knew which
treatment had been allocated. An unblinding mechanism was available if required for emergency
procedures. This was via an interactive voice response system to the Centre for Healthcare Randomised
Trials that held the randomisation list for the trial, which contained study pack numbers and treatment
allocation. Emergency unblinding was required to be performed by a senior clinician.
Treatment group allocation
The study was designed to achieve concealment of allocation. Active GTN sprays were identical to placebo
sprays. Study outcomes were recorded by clinicians and midwives blinded to treatment allocation.
Unblinding was not performed until after data entry was complete, the database was fully checked and
validated and all queries were resolved.
Intervention
Women were required to take two puffs sublingually of either GTN or placebo. Each drug canister contained
a pump mechanism that delivered a metered dose of 400 µg of either GTN or placebo. We chose a sublingual
route because administering GTN via a sublingual spray had previously not been tested and was required by
the HTA during the commissioning of our trial. The intervention was self-administered as a single intervention
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(two puffs of 800 µg active drug or two puffs of placebo spray) as soon as possible after diagnosis of retained
placenta. Both the study drug and the matching placebo were manufactured by Pharmasol Ltd (Liverpool, UK)
and labelled by Sharp Clinical Services (UK) Ltd (Ashby-de-la-Zouch, UK).
Data collection and management
The GOT-IT trial met the requirements of the Data Protection Act 1998.29 Data were collected at each site
by a GOT-IT trained researcher using a standardised case report form. Initially, data were captured in a
paper case report form as well as being entered into the electronic case report form. However, to minimise
duplication, the sponsor requested that use of a full paper case report form should be discontinued and
replaced by an abbreviated paper case report form. Following this change, previously required information
no longer collected on the abbreviated case report form was captured straight from source documentation
and entered directly into the database.
The study collected pre-baseline data (i.e. subject log, eligibility and consent), baseline data (i.e. clinical
observations at baseline, demographics, obstetric history, current pregnancy information, medical history and
medications), clinical observations (at 5 and 15 minutes) and details of placenta delivery, first post-natal day
and discharge information. All data, including discharge questionnaires (see www.journalslibrary.nihr.ac.uk/
programmes/hta/122901/#/), safety data and a 6-week postnatal check data, were entered by research
midwives or clinical data administrators based at each of the sites. The exception to this was postnatal
questionnaire data that were entered by administrators in the trial office (see www.journalslibrary.nihr.ac.uk/
programmes/hta/122901/#/). Participants were identified by a unique five-digit code.
Data validation checks developed within the database flagged missing or erroneous data. In addition, the
trial office undertook regular manual checks of the database and any discrepancies noted were queried
with individual sites. The study had a specific monitoring plan developed by the lead study monitor for
Academic and Clinical Central Office for Research & Development (ACCORD) (joint office for the University
of Edinburgh and NHS Lothian). All sites received an onsite monitoring visit following the recruitment of
four subjects to the trial. The monitoring visit involved reviewing consent forms, confirming participant
eligibility, checking that staff allocated to undertake delegated tasks were appropriately qualified to do so,
checking the quality of data abstraction and visiting the local pharmacy. Outstanding monitoring actions
were logged and a written report was forwarded to the principal investigator following the visit. The onsite
study staff then completed any actions highlighted.
Study assessments
All women received the following assessments prior to randomisation: screening, confirmation of eligibility
(including a brief medical history and concomitant medication check), informed consent, baseline observations
(blood pressure, heart rate, temperature) and a full blood count had to have been taken within the past
24 hours to obtain a baseline haemoglobin level.
Following randomisation (administration of the study intervention), blood pressure, heart rate and temperature
were measured at 5 minutes and 15 minutes. Blood loss was measured from the point of study drug
administration until the woman was transferred to the postnatal area. Prior to hospital discharge, a full
blood count was again collected to measure haemoglobin level and a questionnaire was given to each
woman to complete. The questionnaire was designed to measure patient-rated side effects and patient-
rated satisfaction. Any adverse events (AEs) noted were also recorded.
Women received a further questionnaire 6 weeks later from the trial office. This postnatal questionnaire
was also designed to measure patient satisfaction, side effects and health resource use. Women were
asked to complete and return it to the trial office in a provided prepaid envelope.
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Outcomes
Primary outcome
The primary outcomes were measured over four inter-related domains of clinical, safety, patient sided and
economic.
1. Clinical: the need for manual removal of placenta, defined as the placenta remaining undelivered
15 minutes post study treatment and/or delivery being required within 15 minutes of treatment because
of safety concerns.
2. Safety: measured blood loss between administration of treatment and transfer to the postnatal ward
or another clinical area (e.g. labour ward high dependency).
3. Patient sided: satisfaction with treatment and side-effect profile assessed by questionnaire.
4. Economic: evaluation of possible net incremental costs (or cost savings) to the NHS of using GTN versus
standard practice. Costs included GTN (dose and time to administer the study drug, monitor a woman
and deliver the placenta if effective), manual removal of placenta and further health service resource
use up to 6 weeks post childbirth (as measured by the health service resource-use questionnaire).
Secondary outcomes
1. Clinical outcomes:
¢ fall in haemoglobin level of > 15% between recruitment and the first postnatal day
¢ time from randomisation to delivery of placenta
¢ manual removal of placenta in theatre
¢ need for earlier than planned manual removal of placenta because of clinical concerns
¢ fall in diastolic or systolic blood pressure of > 15 mmHg and/or increase in pulse of > 20 b.p.m.
between baseline observations and 5 and 15 minutes post administration of study treatment
¢ requirement for general anaesthesia
¢ requirement for blood transfusion between the time of delivery and postnatal discharge from
hospital
¢ maternal pyrexia, defined as at least a temperature reading of > 38 °C within 72 hours of delivery
or discharge from hospital, if the hospital discharge occurs prior to 72 hours following delivery
¢ sustained uterine relaxation after the placenta has been removed requiring treatment with
uterotonics.
2. Costs: the mean costs were summarised by treatment allocation group, and the incremental cost
(cost-saving) associated with the use of GTN was estimated using an appropriately specified general
linear model. The cost data was presented alongside the primary and secondary outcome data in a
cost–consequence balance sheet, which indicated which strategy each outcome favoured.
Safety considerations
Adverse events were defined as any untoward medical occurrence in a clinical trial, which does not
necessarily have a causal relationship with an investigational medicinal product.
Adverse reactions were defined as any untoward and unintended response to an investigational medicinal
product that is related to any dose administered to a participant.
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A serious adverse event (SAE), or serious adverse reaction, was defined as any AE or adverse reaction that
at any dose:
l results in the death of the clinical trial participant
l is life-threatening (life-threatening in the definition of a SAE or serious adverse reaction refers to an
event during which the participant was at risk of death at the time of the event; it does not refer to an
event that hypothetically might have caused death if it were more severe)
l requires inpatient hospitalisation, or prolongation of existing hospitalisation
l results in persistent or significant disability or incapacity
l consists of a congenital anomaly or birth defect
l results in any other significant medical event not meeting the criteria above.
Hospitalisations for treatment planned prior to randomisation and hospitalisation for elective treatment of
a pre-existing condition were not considered serious adverse reactions.
A suspected unexpected serious adverse reaction was defined as any adverse reaction that was classified as
serious and was suspected to be caused by the investigational medicinal product. In addition, the reaction
was not consistent with the information about the investigational medicinal product in the summary of
product characteristics.30
Adverse events and SAEs were documented only if they occurred between when the participant signed
the consent form to take part in the study and the 6-week postnatal outcome assessment point. Only AEs
and SAEs that related to the mother were reported. Participants were asked about the occurrence of AEs
and SAEs prior to discharge from the hospital and in the 6-week postnatal questionnaire. The 6-week
postnatal questionnaire also asked participants if they had seen their general practitioner (GP), been
admitted to a hospital or been prescribed any medication. The local principal investigator responsible for
the care of the participant (or delegated clinician) was responsible for assessing the severity, causality and
expectedness of an AE and whether or not the event fulfilled the criteria for reporting it as serious.
Adverse events were documented in the participant’s medical case notes and on the electronic case report
form. All reported AEs were collated and coded by the trial office and the chief investigator had regular
oversight of them.
All SAEs that were observed during the trial were reported within 24 hours of the site becoming aware of
the event. They were reported by the principal site investigator to the sponsor and the trial office and also
entered into the electronic database. All SAEs were followed up until resolution. The chief investigator was
notified of all SAE reports.
For the purposes of this study the following events were not considered SAEs:
l pregnancy
l hospitalisations for treatment planned prior to hospitalisation
l hospitalisations for elective treatment of a pre-existing condition
l decrease in haemoglobin level of > 15% between recruitment and the first postnatal day
l manual removal of placenta in theatre
l the need for earlier than planned manual removal of placenta
l decrease in either systolic or diastolic blood pressure of > 15 mmHg and/or increase in heart rate of
> 20 b.p.m. between baseline and 5 and 15 minutes post administration of active/placebo treatment
l the need for blood transfusion between time of delivery and discharge from hospital
l the need for general anaesthesia
l maternal pyrexia (one or more temperature readings of > 38 °C within 72 hours of delivery or discharge
from hospital if discharge occurs sooner)
l sustained uterine relaxation after removal of placenta requiring uterotonics.
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The SAEs were reported to the Data Monitoring Committee (DMC) and the Trial Steering Committee (TSC)
at regular 6-monthly meetings. The DMC reviewed the data with an unblinded status. If any serious
concerns had arisen about the safety of the data, the chairperson of the DMC would have recommended
to the chairperson of the TSC that the study should be discontinued.
Governance and oversight
The GOT-IT trial was registered on the ISRCTN registry as ISRCTN88609453. Ethics approval was obtained
from the North East – Newcastle and North Tyneside 2 Research Ethics Committee (13/NE/0339). Approval
was also obtained from the Medicines and Health products Regulatory Agency (2013-003819-42) and the
Health Research Authority as well as from the local trust Research and Development Offices. The study
was a commissioned trial funded by the National Institute for Health Research (NIHR) as part of the HTA
programme commissioned call funding stream (reference number 12/29/01).
Statistical methods and trial analysis
Too much uncertainty existed in two crucial parameters to commit to a fixed sample size design. We
believed that the most appropriate primary outcome was the proportion of women needing surgical
intervention for removal of the placenta. However, there was considerable uncertainty as to how many
women who may have been eligible for trial entry would actually go on to require surgery owing to
(1) a lack of knowledge of frequency of spontaneous delivery of the placenta beyond the time frame and
(2) variations in local clinical practice (e.g. logistics and time taken to organise theatre space and skilled
staff to perform manual removal of placenta). The routinely recorded statistics were not sufficiently
detailed for these variables to be accurately determined. In addition, we were very unsure what the
magnitude of the benefit would be from GTN spray. To reflect these uncertainties and give us a design
that was flexible enough to maximise the chance that we would efficiently detect and estimate the true
benefit of treatment in the quickest time with the right number of participants, but equally give ourselves
the controlled opportunity to abandon the trial if it turned out that no worthwhile treatment effect actually
existed (via futility analyses), we proposed a group-sequential design. We believed that the GOT-IT trial had
the ideal design because it enabled us to present the maximum size of the trial that was needed, alongside
a flexible group-sequential approach that would allow the trial to terminate early for one of two scenarios.
The first scenario would have been overwhelming evidence of benefit (owing to a large treatment effect
and/or less variability in the outcome measure). The second scenario would have been due to a suitably
defined futility (i.e. having partially obtained the maximum trial size); we were confident that a large
treatment effect was implausible and that the current estimate of the treatment effect was sufficiently
precise to be convincing, thus allowing the trial to be terminated early.
Ground rules for the statistical analysis
The statistical analysis followed a statistical analysis plan (see www.journalslibrary.nihr.ac.uk/programmes/
hta/122901/#/) that was agreed by the TSC. The interim analyses for the DMC were specified within the
DMC charter, and results of these interim analyses were in strict confidence (no member of the research
group apart from the study statistician was aware of the contents of these analyses). The analysis was
based on the intention-to-treat (i.e. analysed as randomised) principle. Statistical significance was at the
two-sided 5% level with corresponding confidence intervals (CIs) derived.
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Sample size
From discussing with clinical colleagues and listening to mothers and pregnant women, a 10% decrease
in women needing manual removal of placenta would be a sufficient advantage to make it worthwhile
implementing the GTN spray in clinical practice. From a statistical perspective, we knew that the maximum
variability in a binary outcome (i.e. need for surgical intervention: yes or no) would occur at a 50% rate in
the placebo group. On a fixed sample approach with a 90% power and 5% significance level, we would
need 1038 women to demonstrate a 10% change from 50% on placebo to 40% on GTN spray. Allowing
for the multiple sequential looks at the data, a possible maximum sample size of 1078 participants was
needed. Because the primary clinical outcome was recorded within minutes of the intervention being
administered, we anticipated minimal (if any) loss to follow-up and, therefore, no adjustment for missing
data was made.
Group-sequential design
There were many options for deciding on a group-sequential design and the DMC was central to its
implementation and interpretation. Detailed discussions were held with the independent statistician over
the group-sequential design and it was decided to use a Lan–DeMets alpha spending approach31 with
O’Brien–Fleming boundaries.32 We specified a two-sided test, with efficacy and futility boundaries with five
interim looks (the last being the final analysis), equally spaced at 215, 429, 644, 858 and 1073 patients.
Figure 1 shows the stopping boundaries.
Primary/secondary outcome analysis
The group-sequential analysis for the primary clinical outcome was analysed using the statistical
programme East® 6.4.1 (2016; Cytel Inc., Cambridge, MA, USA). For the other primary outcomes, safety
was analysed using ordered logistic regression and patient-sided outcomes were analysed using logistic
regression. Both accounted centre by using cluster robust standard errors. Secondary outcomes were
analysed in a similar way using either a logistic or a linear regression when appropriate. The remainder of
the analysis was undertaken using Stata 14® (StataCorp LP, College Station, TX, USA).
0
St
o
p
p
in
g
 b
o
u
n
d
ar
y:
 Z
 s
ca
le
215 429 644 858 1073
Sample size
– 6
– 4
– 2
0
2
4
6
Efficacy
Futility
Boundaries
FIGURE 1 Stopping boundaries. Black, efficacy boundaries; green, futility boundaries.
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Planned subgroup analyses
The planned subgroup analysis was to explore the possible treatment effect modification through the use
of treatment-by-subgroup interactions all using a stricter two-sided 1% level of statistical significance.
The subgroups were:
l previous caesarean section
l gestation at delivery (< 36 and ≥ 36 weeks’ gestation).
Timing and frequency of analysis
Apart from the primary clinical outcome, a single principal analysis was carried out when the final
participant reached the 6-week time point.
Summary of changes to the project protocol
Changes were made to the project protocol as follows.
Eligibility criteria
1. Protocol V3.0 – substantial amendment 2
Change of exclusion criteria from women having an instrumental delivery to women having an
instrumental delivery in theatre.
2. Protocol V8.0 – substantial amendment 11
The original definition of haemodynamically stable was a systolic blood pressure level of > 100 mmHg
and a pulse of < 110 b.p.m. This definition was changed to satisfy all three definitions:
¢ haemodynamically stable
¢ a heart rate of ≤ 119 b.p.m.
¢ a systolic blood pressure of > 100 mmHg.
3. Protocol V8.0 – substantial amendment 11
Change in exclusion criteria to allow co-enrolment to exist for CTIMP trials, providing there was a
CTIMP–CTIMP agreement between the sponsors and investigators of each trial.
Sample size
1. Minor amendment 9
Minor increase in sample size from 1086 to 1100.
No changes were made to the study objectives, outcomes or statistical parameters throughout the duration
of the trial. In total, 16 substantial amendments and 10 minor amendments were sought, which in addition
to the changes described above, covered changes to the recruitment materials, clarifications and administrative
changes to the protocol.
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Chapter 3 Nested qualitative study within the
internal pilot
A nested qualitative study was undertaken during the internal pilot RCT, the purpose of which,as outlined in the study protocol, was to adjust strategies to:
l maximise recruitment into the main trial
l optimise opportunities for gaining informed consent
l ensure that staff were given appropriate training and support to help promote the successful delivery of
the main trial.
The specific aims and objectives of the qualitative work were as follows.
Aims
l To explore women’s and staff members’ experiences of, and views about, the information and consent
pathway used in the pilot RCT.
l To establish women’s likes and dislikes of the interventions and procedures received in the pilot RCT.
Objectives
l To refine/improve the information and consent pathway used in the substantive trial to maximise
recruitment and informed consent.
l To identify better ways of supporting staff involved in recruitment.
An additional objective outlined in the original protocol was ‘to refine the questionnaire used to assess
patient satisfaction with GTN given for retained placenta’ (reproduced with permission from Denison
et al.33; contains information licensed under the Non-Commercial Government Licence v2.0). However,
as this questionnaire was developed in advance of the pilot trial (and, hence, the qualitative work being
undertaken), the work done to develop and refine the questionnaire is reported separately (see Chapter 6).
Overview comments
The qualitative work was started and completed on schedule, which enabled a full evaluation of the pilot
RCT to be undertaken from women’s and staff members’ perspectives. As outlined further below, feedback
was given to the trial team and participating sites in a timely fashion allowing the incorporation of the
findings and recommendations into the main trial.
Given that recruitment into the pilot study was so successful, the qualitative work gave primacy to:
l exploring women’s and staff views about the recruitment and consent pathway used in the pilot and
how it could be refined for use in the main trial to maximise informed consent
l using findings from interviews with staff to inform the training and support offered to those working
on the main trial to promote successful trial delivery.
The qualitative research also considered why recruitment had been successful in the pilot RCT to help
ensure ongoing success in the main trial.
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In line with the Royal College of Obstetrics and Gynaecology guidelines for undertaking recruitment into
perinatal trials,34 and as per the original trial research proposal, approvals were sought and mechanisms
put in place by the trial team to enable women to access information about the trial during the antenatal
period, using a pathway similar to that developed by Vernon et al.35 However, owing to the timing of the
pilot RCT, it was not possible to interview women who had been exposed to an information and consent
pathway in which they had received trial information during the pregnancy. Instead, the pathway
evaluated in the pilot was one in which women’s first exposure to information was when they were
recruited in the labour wards, following diagnosis of a retained placenta. At the time they were recruited,
these women were given written information about the trial in the form of a one-page summary leaflet
accompanied by a detailed participant information sheet. Women were also provided with a verbal
explanation of the trial by a designated and trained member of recruitment staff that covered all elements
in the participant information sheet and consent form. In recognition of the clinical situation that the
women were in, the trial permitted verbal consent to be given, provided it was followed by written
consent at a later stage.
Qualitative study design
In-depth interviews were used in the qualitative evaluation of the trial’s pilot phase as these afforded the
flexibility needed for participants (staff and women) to raise and discuss issues that they perceived as being
salient, including those unforeseen at the study’s outset.36,37 The use of one-to-one interviews also afforded
privacy, allowing participants to share negative views about the trial’s processes and procedures, should
they have chosen to do so. Data collection and analysis took place concurrently as this enabled the areas
explored in the interviews, and also sampling, to be revised in the light of emerging findings.38,39 Staff and
women’s interviews took place in parallel allowing findings from one respondent group to inform issues
explored with the other.
Sample and recruitment
Recruitment of staff and women started right at the pilot’s outset (i.e. October 2014) and continued to the
end of the pilot (i.e. April 2015). This was done to accommodate the staggered entry of sites into the pilot,
to allow for the full spectrum of experiences of delivering and receiving the pilot to be captured and to
ensure that there was representation of participants (staff and women) from all eight sites that took part
in the pilot. To optimise the recruitment strategies used in the main trial, it had originally been intended to
interview women who had declined participation in the pilot RCT as well as those who chose to take part.
However, there were very few decliners in the pilot (n = 6): two women could not be approached because
the necessary research and development approvals had not been finalised, two were determined by staff
to be unsuitable to approach for clinical reasons and the remaining two chose not to opt-in to the
qualitative research. Therefore, no decliners were interviewed.
In line with our original study plan, women who had taken part in the pilot trial were given recruitment
packs when the research midwives visited them on the wards, or packs were posted out to them if their
discharge from hospital had already taken place. These packs contained a written invitation from the
local principal investigator, information sheet, opt-in form and consent form accompanied by a prepaid
envelope. Of the 49 women who were approached during the pilot, 25 opted in to the study, of whom
22 (45%) were interviewed (the remaining three could not be contacted to arrange an interview time,
despite repeated attempts). Staff who had been involved in recruiting and/or consenting women were sent
recruitment packs containing opt-in forms. Across the centres, these staff comprised obstetricians, research
midwives and midwives. In total, 37 individuals returned their expression of interest and, to the best of
our knowledge, only one staff member actively chose not to opt in to the qualitative study. Of these
37 individuals who opted in, 27 (73%) were selected for interviews, with purposive sampling being used
to ensure that there was representation of staff from all pilot sites, from all disciplinary backgrounds
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(i.e. obstetricians and clinical and research midwives) and who had worked day/night/weekend shifts when
recruitment had taken place. Staff were also approached and selected for interviews if they had experience
of attempting to recruit women into the pilot trial who chose to decline. Although some staff were
interviewed early on in the pilot to enable early recruitment experiences to be reflected on, others were
interviewed nearer the pilot’s completion to allow them to draw on their experiences of trial delivery across
the pilot as a whole.
In both the staff and women samples, recruitment continued until data saturation was achieved (i.e. until
no new findings or themes were identified in new data collected).
Data collection
Interviews were conducted between November 2014 and May 2015. To reduce potential problems with
recall bias, women were interviewed within 4 weeks of having taken part in the pilot trial. Although
women were given the choice of a telephone or face-to-face interview, virtually all (n = 21, 95%) chose
to be interviewed by telephone. As these women later explained, they preferred to be interviewed by
telephone than receive a home visit as this arrangement made it easier for them to cancel and reschedule
at short notice if they had not slept well or needed to attend to their baby. All staff opted to be
interviewed by telephone.
Interviews with both staff and women were informed by topic guides, developed in the light of literature
reviews, inputs from members of the trial team, implementation group and lay advisors, and revised in the
light of emerging findings (see Qualitative study design).38,39 Interviews with women averaged 25 minutes
and those with staff lasted around 45 minutes. In all but two cases (in which the women had to end the
interview early to attend to their baby) all key areas in the topic guides were covered and explored in
depth. All interviews were digitally recorded and transcribed in full for in-depth analysis.
Data analysis
As indicated above, data analysis commenced as soon as data collection began. Data were analysed
thematically (using deductive approaches to capture the material needed to answer our original research
questions and inductive approaches to capture findings and themes that emerged from the data) by Julia
Lawton and Nina Hallowell using the method of constant comparison.39 This entailed individual interviews
being read through repeatedly before being cross-compared to identify issues and experiences, which cut
across different accounts. Comparative analyses of women’s and staff accounts were also undertaken to
identify differences and similarities in their views about the recruitment and consent procedures used in
the trial and the reasons for these. Julia Lawton and Nina Hallowell undertook independent analyses and
wrote separate data analysis reports before meeting to discuss and reach agreement on key findings and
themes to develop a coding frame. The qualitative analysis software package NVivo9 (QSR International,
Warrington, UK) was used to facilitate data coding and retrieval. Coded data sets were subjected to
further, in-depth analysis to identify subthemes and illustrative quotations. Illustrative quotations were
given pseudonyms to anonymise them, as follows: women were allocated a name (e.g. Ellie), doctors were
referred to as Dr X (e.g. Dr H), midwives were referred to using a letter (e.g. O) and research midwives as
researcher (e.g. Research A).
Implementation group
An implementation group was set up to enable fast and effective application of the qualitative findings in
the main trial. This group comprised the chief investigator, other trial team co-investigators, the trial
manager, a patient representative and representatives (research midwives) from all eight participating
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centres in the pilot. The implementation group was convened prior to the qualitative data phase to help
refine the interview topic guides and to discuss sampling strategies, with input from some members
sought by e-mail. A face-to-face meeting took place at the end of the pilot phase to enable the qualitative
researchers (Nina Hallowell and Julia Lawton) to feedback their findings to the group so that a series of
recommendations would be made for implementation into the main trial.
Findings
Full details of the final samples of women and staff who took part in the interviews are provided in
Tables 1 and 2.
TABLE 1 Participant characteristics: women
Demographic
Number of participants falling
into this demographic (N= 22) % of total
Age (years)
18–24 3 14
25–29 5 23
30–34 8 36
35–40 6 27
Mean: range 30.7 18–40
Ethnic group
White British 17 77
South-east Asian 2 9
Other 3 14
Marital status
Husband/de facto partner 19 86
No current partner 3 14
Highest education level
School 7 32
Further education 2 9
Degree 8 36
Higher degree 5 23
Occupation
No paid employment 4 18
Self-employed 1 5
Office/administrative 5 23
Professional 4 18
Semiprofessional 8 36
Previous birthing experiences
Primigravida 9 41
Previous retained placenta 5 23
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One of the sites experienced a delay in recruitment with only two women randomised during the period
November 2014–April 2015. Both women refused our invitation to interview, so the qualitative study
included women (n = 22) from only seven out of the eight pilot sites. Another site did not allow us to
recruit until April 2015 so our final sample included between one and seven (mode three) women
recruited from each of the seven sites. As can be seen from Table 1, we achieved a diverse sample of
women in terms of age (18–40 years, mean 31 years), occupation, education, ethnicity, first/other
pregnancy and previous experience of retained placenta.
Similarly, we achieved good representation of different types of staff members: midwives, research
midwives and obstetricians (including consultants, registrars and specialist trainees) (see Table 2). A total
of 27 staff members were interviewed: between one and six (mode three) at each site. Research midwives
from all eight pilot sites were interviewed, recruiting obstetricians (including three consultants) from
seven sites and midwives (including two labour ward co-ordinators) from a further four sites. At least one
research midwife and one obstetrician were interviewed from each of the pilot sites, with the exception
of one site. Although 96% of the sample was educated to degree level or above, the degree of clinical
and research experience was variable. Three staff members had dealt with women declining randomisation
to the GOT-IT trial.
Research questions
1. What are women’s views about the timing of delivery and content of the information provided during
the pilot RCT? In what ways do they think the information and consent pathway could be improved,
and why?
2. Why did women agree or decline to take part in the pilot RCT?
TABLE 2 Participant characteristics: staff
Staff characteristic
Number of participants falling
into this characteristic (N= 27) % of total
Staff job
Obstetricians 10 37
Clinical midwives 6 22
Research midwives 11 41
Education
Professional qualifications 1 4
Degree 26 96
Higher degree 5 19
Time in current post (years)
0–2 9 41
2.5–5 13 48
5.5–10 2 7
> 10 3 11
No previous research experience
Obstetricians 4 15
Clinical midwives 2 7
Research midwives 0 0
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3. Does the consent process give women a good understanding of the trial – if not how could this
understanding be improved?
4. What are women’s likes and dislikes of the trial interventions and procedures?
5. What are staff member’s experiences and views of recruiting women with retained placenta into the
pilot RCT; how do they think the recruitment/consenting procedures might be improved; how, if at all,
could they be better supported to undertake future recruitment?
6. Do any unforeseen difficulties/issues arise during the pilot RCT; how might these be overcome in the
substantive RCT?
The findings presented below are structured under our original research questions. To safeguard
participants’ confidentiality, pseudonyms are used throughout this report and all identifying information
has been removed or altered to preserve anonymity.
Since qualitative data analysis was completed, three papers have been published that report key findings
from the analyses.25–27 Given the overlaps between the contents of these papers and the material presented
in this chapter, the three papers are cross-referenced in various places. Readers wishing to access more
details about particular findings and additional quotes should refer to these papers.
Research questions 1 and 3
The answers to research questions 1 and 3 have been combined in this final report owing to the strong
overlaps in the material.
Women’s views about the information and consent pathway used in the pilot phase
Most women suggested that the information and consent pathway used in the pilot could be improved in
the main trial to optimise informed consent, the exception being a small minority (n = 3) who had relatively
fast and straightforward births with minimal requirement for pain management:
The actual labour was 2 and a half hours, very, very quick in the end. Once she decided she was
coming, she came. There was no pain relief, just some gas and air and out she came.
Alison
It all happened within 5 hours . . . I just took paracetamol in the morning before I left. I had a couple
of, you know, breaths from the gas and air, but maybe only three or four times and then I pushed and
that was that. Sounds easy doesn’t it?
Ellie
These women described how, owing to their straightforward birthing experiences, they had been reasonably
rested and mentally alert when they had been approached to take part in the trial. This, as these women
went on to suggest, had been reflected in their ability to digest the written and verbal information given by
recruiting staff and ask questions before making their decision:
I asked for a little bit more information and read the form . . . I was quite happy to read it through
myself and felt I was able to logically make the decision about whether to give it a go.
Heather
So they said that there’s this project with the university . . . and I said, ‘yeah, let’s see the leaflet’.
And I read the leaflet. That it would be a placebo or, you know, the medication that they give to me.
And then there was a doctor, after I read the leaflet, who explained it again: what was basically in
the leaflet . . . and, well, before I made my decision, I asked if the medication has any impact on
breastfeeding; if there’s anything that can go into the milk, for example.
Ellie
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Although these women conveyed satisfaction with the recruitment/consent pathway and felt that it had
worked well in their particular case, they also suggested that other women who had just given birth might
not be as well placed as they had been to consider trial information carefully and give fully informed
consent. To make this point, Heather, for instance, juxtaposed her most recent birthing experience with
that of her previous delivery, during which she had been in labour for > 36 hours:
I was fine signing the form but, to be fair, if I’d been in the situation like with my last delivery I don’t
think I’d have been able to understand it all and to really understand what it was about, because I
wasn’t quite as alert as this time round . . . Last time I fainted, and this time I was really, you know,
I was really feeling well because everything went so quickly. I was absolutely fine, you could have
taken me to the pub if you’d wanted to [laughter].
Heather
Indeed, in contrast to the minority described above, most of the women who were interviewed described
a birthing experience that had left them physically and emotionally exhausted and for which, in some
cases, analgesics had been required.27 These women also discussed how, owing to all of the activity taking
place around them, they had often been very distracted when they had been approached to take part in
their trial:
I think they were just in a hurry to get the placenta out . . . they had quite a lot of doctors in and they
kept telling me about the risk of infection and that they were having to – if nothing else worked –
take me to theatre straight away.
Arlene
As a consequence of these kind of birthing experiences, women described liking and appreciating having
been given summary information about the trial at the time of recruitment rather than having to read
a full participant information sheet. Many also highlighted the benefits of having had staff present to
provide verbal descriptions and explanations of the trial because, as they observed, they had simply been
too tired to read written information themselves.26,27
Women’s views about giving and gaining informed consent
Although women praised the content and mode of delivery of the information given at the time of
recruitment, the majority (with the exception of those who had straightforward and relatively pain-free
births) also noted that, despite the efforts of staff to convey information about the trial in a clear and
accessible way, they had simply been too tired, distracted and/or emotionally overwhelmed to take all this
information in:
There wasn’t anything that anybody could have done at that time . . . because giving me anything to
sort of read, or consent to was pretty pointless to be honest, because I had no idea what was going
on, or what I was agreeing to.
Trina
Just cause after I had him, because of the amount of gas and air that I had had, I was still, I wasn’t
really understanding what people were saying to me.
Arlene
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Indeed, although most women were able to recall a basic understanding of the trial, including, in many
cases, use of a placebo and a randomisation process, most also described how they had not absorbed
detailed information about the trial, including information relating to possible risks or side effects of
taking GTN:
Interviewer: And did he say anything about what was in the spray and what the risks were, did he
explain that?
Tracey: Probably but I was out of it, I was tired, I was fed up . . . I was trying to feed [baby’s name]
and I just had to get it [the placenta] out of me. I remember saying, ‘I don’t care how it works, just get
it out’.
As a consequence of poor and limited ability to digest and consider all of the information provided, some
women also questioned if, in retrospect, their consent had been fully informed.27 These women reflected
on how, at the time that they were recruited, they had been in what they recognised, with hindsight, to
have been a vulnerable situation. Specifically, women discussed how they had been desperate to avoid
going to theatre as this would have meant leaving their babies and exposing themselves to what they saw
as invasive and sometimes frightening medical procedures:
And she said that I could try this new drug and it’s the last resort before an epidural to take the
placenta out. So I just thought, ‘oh my god I don’t want an epidural’ so I tried it . . . The word epidural,
you’re going to try anything . . . I was frightened to death of an epidural, and I’d managed to keep
everything so natural so far . . . You know, just a few puffs of gas and air.
Hannah
Consequently and, as detailed elsewhere,27 most of these women said that, owing to their being in a
vulnerable and/or desperate state, they had tended to make their decision to take part in the trial very
quickly, in most cases without asking questions or consulting and seeking the opinion and views of other
people in the room, such as their partners:
The thought of going to theatre terrified me, and all I wanted to do was to be with my baby, so I just
said yes, I didn’t even hesitate. I really didn’t think about it at all.
Hannah
Because for me it was just a really quick decision that I didn’t really think about, it was just a quick
‘yes’ and, in hindsight, I just think it would have been good to have taken a bit more time to process
the information and discuss it with my partner . . . Because he said to me later, you know, ‘I don’t
know why you agreed with it’ . . . because for him it was a case of ‘you don’t want to try something
that’s unknown’.
Lynne
Thus, again, with hindsight, these kinds of experiences led women to question if their decision to take part
had been fully informed, although, as detailed elsewhere, these women were also keen to emphasise that
they did feel that they had given their consent willingly and freely to take part in the trial.26
Improving the information and consent pathway: extending information-giving into the
antenatal period
In the light of their recruitment experiences, most women suggested that their decision-making and,
hence, ability to give fully informed consent could have potentially been enhanced had they been exposed
to trial information during the antenatal period.25 Specifically, women discussed how this earlier exposure
to trial information would have allowed them to consider it at a time when they were better placed
mentally and emotionally to digest and reflect on it. Some also suggested that this earlier exposure might
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have enabled them to discuss their potential trial participation more fully with others and to draw on
thinking and decision-making made when they were not in such a panicked and desperate state:
I think it’s probably best off discussed in your maternity bit before . . . you know when you’re in labour
and the word of an epidural, you’re going to try it, you’re going to try anything, because you’re panicking
and you’re desperate. And I think that really, you know, you’re not in your best frame of mind to listen
either, because I was still contracting at that time to get that placenta, I was still contracting but it wasn’t
coming out. So, I think if you say, if you just mentioned it in like your maternity, like ‘if this happened,
if your placenta got stuck or if . . .’ I think it would be probably best off mentioned then than actually
when you’re in your full labour.
Hannah
I think it was a bit late after giving birth cause I wouldn’t, I didn’t concentrate. Like I said, I was tired,
just had a baby, didn’t really know what was going to happen next. So, em, that’s what I would have
liked, I’d have liked to have the information before, so I could kind of go through it in my mind, know
what I’ve been preparing myself for. And obviously if I was willing to take part.
Liz
Some women also discussed the potential benefits of making women more aware of retained placentas
during pregnancy so that, as Tricia explained, ‘it’s not as much of a shock, because I had no idea’. As
these women suggested, ameliorating shock reactions in this way might help to promote more informed
decision-making to take part in the trial because, as Helen observed:
You wouldn’t be panicking so much at the time. I didn’t know what would happen if it got stuck or
anything like that. So I think I’d maybe have been better if I knew what could happen as I probably
would have been more prepared, obviously not been as worried about it, so I would have been better
able to concentrate.
Helen
When asked when the best time would be to give women information before labour, most suggested the
later stages of the antenatal period. This is because, as several women noted, earlier on during pregnancy,
such as at a booking appointment, would be too premature because, at that point in time, not all women
are confident a pregnancy will go to term.27 It was also suggested that the later stages of pregnancy would
be a good time to be exposed to information about the trial, as this was when birth plans were drawn up
and, hence, potential birthing complications discussed, including, in some cases, retained placentas:
Em, well the midwife speaks to you about – because obviously she tells you that your placenta can get
stuck and I think if she had some information then she would maybe just give you a leaflet and talk to
you about it, when she’s talking about the placenta . . . I’m sure she spoke to me about it when I was
30 weeks.
Arlene
Some women who had had a retained placenta previously also suggested that, owing to their increased risk
of having one again, women, such as themselves, could be targeted for information-giving about the trial:
And especially since I’d had a retained placenta before, it would have been good to have had
someone like just to flag up the kind of high-risk people who might be eligible at that time might be
. . . would probably be better.
Tricia
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Although most women highlighted the potential benefits of being given information during the antenatal
period, there were some who questioned the potential merits and/or efficacy of this. Such women observed
that, because a retained placenta is a relatively rare condition, being given information might be unduly
burdensome and/or this information might not be engaged with at that time:
I’m not sure what the percentage is, how many women have a retained placenta? It would make
sense if it happens a lot to kind of raise the awareness. And, you know, there are so many things that
can occur during labour. Em, I’m not sure how many leaflets you can read in advance, you know what
I mean, you get, you already get so many things about what can happen. So I don’t know if I would
have looked into it in much detail.
Heather
However, as described previously,26 even when women were ambivalent about the potential benefits
about being given information during the antenatal period in their particular case, they also emphasised
the importance of exposing women to trial information so they could decide for themselves whether or
not they wished to engage with it.27 The majority, in contrast, indicated that, for them, the antenatal
period had been a time when they had been ‘information hungry’; that is, they had been very receptive to
receiving and accessing information to make informed choices regarding their pregnancy and birth. This
included Susie, who described how she had undertaken her own research and found out about retained
placentas during her pregnancy, and Trina, who considered discussions about birthing complications to be
an important and necessary part of responsible birth planning:
Yeah, I think so because obviously, like I say, I’d done a lot of research into it but I still didn’t know
about the GOT-IT and I didn’t know that that was an option. So yeah, I think so because then if I
would have been approached with it, you know, me and my husband could have maybe talked about
it beforehand and said, you know ‘if I did need the spray, would I have it?’.
Susie
So yeah, I do think with the antenatal stuff and midwives possibly making that a little bit – or even just
a leaflet in with your pregnancy notes. Because we get leaflets about looking out for pre-eclampsia.
You know we get leaflets about looking out for gestational diabetes and things like that, you know
throughout your pregnancy, so we can make informed choices.
Trina
Improving the information and consent pathway: extending information-giving into the
early postnatal period
Owing to their limited ability to absorb or retain information about the trial at the time of recruitment,
some women also highlighted the benefits of revisiting and rereading written materials after the trial.
For this reason, women who had lost or misplaced their packs following recruitment described
appreciating having been given new ones prior to their discharge from hospital.26 Those who had
experienced a postpartum haemorrhage, or another complication, attached particular importance to
revisiting trial information. Not only did these women describe ensuing upset and distress but they also
discussed how their experiences had led them to question and regret their decision to take part in the trial
and, more specifically, their failure to engage with possible risks and side effects of taking GTN.26 As well
as valuing opportunities to revisit trial materials, these women described needing and benefiting from
debriefing sessions with staff to discuss what had happened to them. They described these sessions as
enabling them to understand whether the complications they had experienced had been due to having
had a retained placenta or if they could be explained by having taken GTN.26 As these women indicated,
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they were principally looking for reassurance that, were they to give birth again, they would be unlikely to
encounter similar problems:
I don’t know whether it was due to the spray or because of the condition itself, I just bled, I’ve no idea
. . . because what worries me if there is a chance I could have another one [child] and it worries me
that if I did have another one, could it happen again? Because, you know, if I thought, well it’s the
drug that caused the reaction, I’d feel better because I’d think, ‘well, you know it’s not going to
happen again’, hence, a 10-minute conversation really would have been nice, would have made me
feel a bit more at ease about it all.
Lynne
In general, women benefited from receiving input from staff following trial participation. In some sites,
this occurred because treating clinical staff are required to visit and debrief patients who have had a
postpartum complication, such as retained placenta, prior to their discharge. In addition, as part of the
trial, research midwives visited trial participants prior to their discharge whenever this was possible to
deliver questionnaires, approach women about the qualitative study and check they were doing well.
However, if women were admitted on a Friday, they could be discharged over the weekend prior to the
research midwife doing her rounds. Thus, in a few cases, such as Lynne’s above, there was the chance that
women who experienced a complication could be discharged without having the opportunity to discuss
their experiences with a staff member (however, see Research question 6).
Research question 2
Reasons for agreeing
As already indicated above and detailed elsewhere,26 women provided very similar reasons for taking part
in the trial. Principally, women described having been very anxious about, and wishing to avoid, going to
theatre if at all possible. Indeed, it was for this reason that some women also conveyed the belief that by
offering them the chance to take part in the trial, trial staff had been working in their best personal and
clinical interests.26
Related to their desire to avoid going to theatre, women discussed how they had wanted to do everything
possible to be there for, and avoid separation from, their newborn baby:
I just wanted to get this placenta out, I was fed up and I just wanted to hold my baby.
Lynne
And to be honest, the reason I said yes, was because obviously the thought of theatre wasn’t nice and
I really didn’t want to leave the baby.
Susie
Some women also described their efforts to keep their birthing experience as natural as possible, and conveyed
their sense of achievement when they had avoided all but minimal pain management (gas and air) during
the birth. Although such women recognised that GTN comprised a medical procedure (see below) they
described having been motivated to take part in the trial, as they considered taking a spray to be a much
less invasive and medicalised option than a theatre visit and accompanying epidural:
I didn’t really want to go to theatre having managed to go through labour normally and naturally . . .
I didn’t really want to have an epidural, I just wanted to get on with it and keep it as natural as
possible. So I thought, ‘right, OK’, so that basically was my reasons for consenting to it.
Lynne
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Although women were motivated primarily by their own needs and those of their newborn, many were
also keen to emphasise that they had welcomed their participation in the trial as they saw the study as a
useful and well-intended piece of research that might help prevent other women from having to go to
theatre in the future:26
June: And it being a research programme, it’s more like a research, at least it was good to be part of
the research so that was why I went for it.
Interviewer: Why was it good to be part of the research?
June: Well, it’s good to be part so that at least it will help in, well, I’d say it will help to develop so
many things, you know? . . . So I think it’s good for somebody to at least try something new and see
whether that something new can be good to help out in so many things. So that’s just like when
maybe researches are made with regards to like this Ebola crisis now, there’s so many researches that
have been undergone and so many people are contributing to it just to eventually get a drug that
would combat the problem. So I think the research is just more helping out to see what can be done
to prevent a woman who has a retained placenta, to prevent her from going into the theatre.
Interviewer: So why did you decide to take part in GOT-IT?
Anna: ‘Cause it’d be great to know if I have another baby and I have – if I have another baby I’m likely
to have a retained placenta having had one, so if they answer the question by then . . . and I guess we
all benefit from making, finding answers that make babies and mothers safer.
Women also noted that trial participation required very little from them because they had to wait an
additional 15 minutes only before a referral to theatre in the event of the spray not working, and taking
the spray was considered a very simple and easy thing to do.
Reasons for declining
Six women declined participation in three sites during the pilot phase; however, as described earlier, it was
not possible for us to interview any of these women. Unfortunately, we were also unable to interview
members of staff who attempted to recruit women at the first site, but did interview staff at the others,
including those who had been directly involved in explaining the trial to these women, and others who
had either observed these failed attempts at recruitment or heard about them.
Staff reported three main reasons for women declining trial participation. The first was primarily to do with
women’s anxieties about their infant’s health. Staff described one instance when a woman refused to take
part because her baby had been taken to the neonatal intensive care unit. This woman was described as
anxious, overwhelmed and unable or unwilling to make a further decision at that time:
The one that I was around for, her baby was rushed off to neonatal unit straight after delivery in an
emergency. So the baby was born in poor condition and was whisked away to the neonatal unit.
So then she went on to have a retained placenta. So the registrar that actually tried to consent her,
she’s very, very positive, very keen for the study. So she said – and I spoke to her – but she said that
the woman just said that it was too much for her to think about it at the time. Obviously she was
upset. The baby had just been whisked away. And even though the potential was that it might stop
her going to theatre, she was more that she didn’t have – she wasn’t able to think about it and make
a decision at that time. So she just said she would rather not.
O
In a couple of cases, women had already tried a number of different methods to deliver the placenta, and
staff described the women as too tired and exhausted and/or not wanting to waste more time waiting to
deliver their placenta. Staff believed that these women had declined participation in the GOT-IT trial
NESTED QUALITATIVE STUDY WITHIN THE INTERNAL PILOT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
because they felt that this would delay them from being able to hold and bond with their baby. The
midwife who had been involved with one of these cases (see below) speculated that if had she mentioned
the trial sooner, namely, immediately following the diagnosis of retained placenta, then the woman
concerned might have been more willing to consider it after she had exhausted other options:
We tried other options. We tried putting baby to breast, jasmine compress, we’ve got her sat up on
the birthing stool. We put her legs into McRoberts. We got her standing, and it just wasn’t happening
basically, and eventually it was decided that obviously she would need to be going to theatre to get
the placenta out, but when it was offered for the GOT-IT – for the trial, I don’t know if it had just
been too long where we’d been trying, but she was just, she’d just had enough basically. She wanted
to just be able to be with her baby properly and I think she just probably thought the manual removal
had been offered. So I think she probably just thought, ‘I just want it over and done wi’ . . . I just think
if I’d have offered it sooner it might have been a success, the lady might have taken it. So in hindsight
it’s probably made me realise that I should have probably opened me mouth a bit sooner [both laugh].
B
The final reason given for women refusing trial participation was that some women were more ‘difficult’ to
engage than others:
The one who declined I don’t recall that she particularly asked many questions of me because she was
so kind of negative about anything it was more of a straight no rather than mulling it over.
Dr S
Staff described a woman at another site who had rebuffed all attempts to describe the trial to her.
Arguably, this woman can be seen as an indirect decliner because she received minimal information about
the trial and its procedures:
And she [doctor] did say to me, you know, this lady’s been – it’s probably not the right wording
what – this lady’s being quite difficult, hasn’t really wanted anything that we’re doing, and I think it’s
probably better that you don’t come in the room . . . And then she just came back and said, to be
honest, she wasn’t letting me even try and have the conversation. She just kept shutting me up and
saying, ‘no I don’t want to be part of it. You’re confusing me. Stop adding more’.
P
Unfortunately, as there were so few women who declined trial participation during the pilot phase of the
trial, and none agreed to participate in the qualitative study, we can base our analysis only on staff
observations and reports.
Research question 4
Trial procedures
Women raised very few concerns about trial procedures; indeed, as described above, the quality and
content of the materials given at the time of recruitment were widely and almost uniformly praised, as was
the method of delivery of trial information (i.e. verbal as well as written). However, as also documented
above, most women did highlight the potential benefits of changing the timing of the delivery of trial
information so that this information could be accessed in the antenatal and postpartum periods.
Most women said that they had been happy to sign a consent form at the time of recruitment and presented
this aspect of their trial participation as having been straightforward and unproblematic. However, a small
minority conveyed a strong preference for a verbal consent procedure to have been used in their particular
case, because of exhaustion or complications such as bleeding.
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Trial interventions
In general, women perceived the trial intervention (i.e. ‘the spray’/GTN) to have been easy and simple to
administer, and as having been preferable to taking a tablet or being injected:
It was very straightforward, literally just a spray under the tongue, so it wasn’t invasive, it wasn’t
painful or anything like that . . . I actually quite liked the fact that it was just you know, quite easy for
me to just literally open my mouth and lift up my tongue, kind of thing. You know there was no
having to swallow tablets, there was no injection or anything like that.
Kirsty
In some cases, the ease and simplicity of administering the spray was also described as having facilitated a
decision to take part in the trial, with some women noting that they might not have agreed to participate
(or not agreed so readily) had a significantly more invasive procedure been involved:
Em, well it was – because it was a spray under my tongue it was easy, so it was fine. If they’d said,
‘it’s an injection’ yes I probably would have still had it. If they’d have said, it’s something that’s
inserted manually, I would have probably said, ‘maybe not actually’. Do you know what I mean? If it
was something that was more, em it was more invasive then probably not. But a spray under my
tongue, in the grand scheme of what had just happened was fine.
Alison
Some women also described having prior knowledge of GTN, either by virtue of being a health
professional or because they had a friend or relative with angina who used the drug. As these women
noted, this prior knowledge had offered confidence and reassurance regarding the drug’s potential safety,
with some, including Anna (who was medically trained), also noting how this prior knowledge had
facilitated a quick decision to take part:
I think I made it instantly, cause – because it was just, well I say this, but it was just GTN but I mean
if it was something a bit weirder, if it was a medication that I maybe wasn’t so familiar with I’d never
prescribed myself, that I didn’t really know the side effects, if it was something quite new, I think
I would have asked more, well ‘is it going to get into my milk? Will it get into the baby?’ and a bit
more about the side effects. And how new it is. If it was something really, really new I might have
chickened out because there’s just more unknowns.
Anna
Although women’s views about the intervention drug and its method of administration were mostly very
positive, some, as indicated earlier, did question if, in retrospect, they had not paid adequate consideration
to the possible risks and side effects of taking GTN. This included those who went on to experience
complications during the trial (see above). There were also some women, such as Tricia, who shared a
(mis)perception that because the drug was a spray, which was simply administered under the tongue,
it had to be relatively benign in terms of its potential impact on the body:
I think because it was just a spray. I know that shouldn’t make a difference but if it had been a jag or
a tablet it might have been different I think. I think I was thinking of it as quite . . . not invasive, just
the fact you’re spraying my tongue . . . it didn’t seem as scary almost . . . obviously it should be going
down to affect where it needs to affect but with a tablet it’s going right into your body. I know it’s a
wee bit daft thinking that really.
Tricia
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Research question 5
Experiences and views of recruitment
As discussed in research question 6, because randomisation to the GOT-IT trial takes place in the
immediate postpartum period, trial recruitment and the delivery of the trial intervention requires the
involvement of clinical staff. Clinical staff were very positive about recruiting to the GOT-IT trial. It was seen
as an easy study to recruit to because the intervention is straightforward, relatively non-invasive, familiar –
and, therefore, perceived as safe – and everyone, both the women and clinical staff, wants it to work:25,26
I feel its quite an easy thing to approach women about, I don’t think it’s a difficult, a difficult sell, if
you like I don’t think it’s asking a lot of people and I think most people are very keen to be involved in
research and also if they think it’s going to stop them having to go to theatre they’re very keen!
Dr A
Staff described the trial as easy to explain to potential participants owing to the simple nature of the
intervention and the trial procedures. Hence, most were very confident that the women they recruited had
received enough information so that they had an adequate understanding on which to base their decision
about trial participation, despite having just given birth:26
As long as you explain it slowly and clearly and don’t overdo it then I think it’s fine, that’s probably the
level you should be aiming for when somebody’s just had a baby. I don’t mean that in a condescending
way, I just mean they are exhausted and they’ve often been up for 1 or 2 days so giving them too much
information is unfair isn’t it . . . All they need to know is that it’s safe but you may or may not get it, it is
a bit of spray and it won’t alter the outcome other than it might reduce [you] going to theatre.
Dr F
Staff were asked about the types and amount of information about the trial that they perceived as
necessary and sufficient for women to give informed consent in the postpartum period. They said this
usually involved providing women with a brief account of uncertainty regarding the effectiveness of the
trial drug, the possibility of visiting theatre for a manual removal, a short account of randomisation and
use of placebo and any side effects they might experience from GTN:26
I think they just need to know that it may or may not work, that you may still end up with the same
treatment that you’ve had anyway, that it’s a relatively safe drug but you may get some side effects.
Dr F
I think I just had said that, it’s a trial, so you might get the real thing, or you might get a fake.
And I don’t know which one you’ll get. We’ll never know which one you had.
Dr B
When asked about which trial materials that they had found useful when recruiting, many staff said that
they had used the summary information sheets, rather than the full patient information leaflets, as they
felt the former contained the right amount of information about the trial for women to take in at this
particular time. They said they had also given women/their birthing partner the full information leaflet
either at the time of recruitment (consenting doctors) or before discharge from the hospital (research
midwives):
I just keep it as simple as I can because there’s that leaflet that’s really detailed and I think that’s a
little bit beyond the women maybe when they’ve just had a baby just because they’re tired and, you
know if they’ve had opiates and stuff as well they won’t really be in the mood for reading that will
they? There’s a simplified version isn’t there which is much more straight forward and I think that’s
probably the level that you should be aiming for isn’t it when somebody has just had a baby.
Dr F
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However, although most clinical staff felt that they had obtained informed consent from women they
recruited, a few acknowledged the difficulties of establishing valid informed consent when women had
just undergone a long and painful labour and were still under the influence of analgesia:
Someone who’s maybe a bit distressed or a bit more tired, the fact that she has to go after they’ve
delivered the baby, after going through the delivery, then they might not want to – they might not want
to listen. And they might not want to read things. That’s – I think that’s the disadvantage of it that it’s
something it’s going to be done after delivery where the woman is exhausted most of the time.
Dr C
One staff member, who had consented a number of women, differentiated between women’s understanding
of trial design and the risks of the trial intervention and other non-clinical aspects of the trial. Dr J was
particularly worried about women’s ability to understand some of the less immediate risks of participation,
such as data extraction, data use and the fact that they would not benefit financially from participation:
I found it really difficult to talk to patients especially when they’re so much in pain. And when you tell
them to sign a consent form with so much information in there it’s difficult for them to fully understand
what they’re supposed to do, and what they’re signing for . . . when patients have just delivered their
baby they mostly go into a bit of like adrenaline rush and then they – shiver and it’s difficult for me to
relay and to tell them everything in the consent form and also for them to read the leaflet. So basically
I’m just trying to push this trial without them fully understanding what the trial’s all about.
Dr J
As noted above, given the clinical situation, the GOT-IT trial protocol allows for women to give verbal
consent to study participation, provided that this is supplemented by written consent at a later time.
However, even though the staff were confident that providing women with a verbal description of trial
procedures was sufficient for gaining their informed consent at this time,27 some, particularly the more
junior doctors, were not prepared to rely solely on women’s verbal consent in this context, although some
women said they would have preferred this (see Research question 4).27 As detailed elsewhere, staff
reservations stemmed from concerns about potential litigation and the need to have documented consent
to present as evidence.27
Perhaps unsurprisingly, Dr J, who had expressed concern about women’s understanding of the non-clinical
aspects of the trial, was pleased to learn that the GOT-IT consent pathway permitted a staggered
consenting process (i.e. verbal followed by written consent), if necessary.
Potential improvements to consent procedures
Although most of the staff interviewed were happy with the consent pathway employed in the pilot
phase,26,27 many of the women interviewed said that they would have liked to have been informed about
the possibility of having a retained placenta and the trial earlier in their pregnancy. We asked staff
members what they thought of this suggestion and also explored their preferences regarding the timing
of information giving.
As we have noted elsewhere, in contrast to the women, staff were either strongly opposed to or
ambivalent about providing individualised trial information antenatally:26
Well if we’re talking to people beforehand and saying, oh by the way, after you’ve had a vaginal delivery
you might have your placenta being stuck and then we’re running this trial whereby you can choose to
have a drug or not. And if it doesn’t work then we take you to theatre. I think my feeling would be
actually that, given that the vast majority of those women that that won’t happen to, in some ways the
sort of increase in maternal anxiety that you would cause by even mentioning these things in advance.
My feeling was that it’s appropriate to counsel at the point that we’re doing at the moment.
Dr G
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It was suggested that even if information were to be made available to women earlier in pregnancy
(e.g. trial leaflets placed in booking packs or discussions about the trial) most would not engage with it
because they are given so much information in their antenatal appointments:
From experience in the antenatal period, women are bombarded with so much information they
struggle to take it in and there’s certainly good evidence that written information very few people
actually read, they go on to the websites which show them nice photos of babies and things and they
don’t necessarily read the information.
Dr H
Many staff members pointed out that receiving information about retained placenta and the GOT-IT trial
may cause women undue worries about the impending birth:
That’s a difficult one I think. Because they’re given so much information, the women, that it’s hard
for them to take it all on board. And I think if you go round – you certainly couldn’t go round telling
every single woman, that just in case you have a retained placenta we’re taking part in this trial.
‘Cause then you wouldn’t want to frighten them. And you know, it’s a small number of them that
will actually end up having a retained placenta.
G
As G suggests, retained placenta is an infrequent postpartum complication and many of the staff we
interviewed talked about the resource implications of ensuring that all women receive information about
the trial during the later stages of pregnancy, when only a small proportion might benefit:
It’s just resources as well, isn’t it? I mean if you give everybody information leaflets coming through
antenatal clinic about retained placenta for, in comparison, a minimal number that will have a retained
placenta, it seems a lot of work and a lot of paperwork. With regards to making them worried, no I
think education’s a good thing. I don’t think it’d particularly make women worried. I think women do
generally want to be informed of what trials we’re running and what’s on offer to them, so they can
make their own decision really. So I don’t think that’s a problem. It’s just really giving everybody some
sort of information for a small number of people. I think that’s the only problem.
I
Although staff were resistant to the idea of providing individualised trial information antenatally, many agreed
that it would help the consenting process if women were aware that the GOT-IT trial was taking place in the
site. Thus, staff suggested raising general awareness about the trial by advertising the presence of the trial in
the site by using posters in antenatal clinics, triaging areas and birth centres as well as advertising on the
trust’s social media sites. This is a practice that many sites adopted during the pilot phase. This was seen as a
compromise that would allow interested women to access more detailed trial information for themselves and
other women to avoid what they might perceive as potentially anxiety-provoking or irrelevant information:
It’s a minority of women isn’t it? So I don’t want to unduly worry. You know that’s the problem with
giving information about research studies that only are applicable to a small number. You’re worried:
are you going to worry people unnecessarily? No I don’t think you will. I think because we had posters
up saying ‘we’re doing a study on retained placenta, when the placenta doesn’t come out after
delivery’. And, you know, ‘if you go in the study the benefits are: you may not need’ – yeah I think
there’s no harm with posters or leaflets around. I think posters might be better in some ways.
Dr I
A few members of staff, in contrast, such as Dr C, felt that the trial should be explicitly brought to
women’s attention when they arrived in the labour ward/birth centre:
Interviewer: Do you think there is a different time at which women could be given this information?
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Dr C: Yeah. that’s what I was going to come to. I think they should be informed, you probably tell me
oh you shouldn’t give it to all women. But I think they should know that a trial is going on in the delivery
unit that they’re in. And if the situation has to happen, then you will be informed about so and so. And I
think it’s better to give the information before rather than just after they’ve delivered the baby.
Interviewer: At what point do you think it should happen before?
Dr C: I think they should be informed on arrival to a labour ward. I don’t think it’s something that you
can give antenatally, in the antenatal clinics, because I don’t think it would make any sense to women.
Others felt that information could be given to women even earlier in the care pathway and they could be
made aware of the trial during their antenatal appointments. One site had acted on this and said that
posters and information about the GOT-IT trial were not only available in the labour wards and/or triage
areas in the hospital but also in the community bases:
We’ve got them in every room in the birth centre. We’ve sent posters out antenatally to the
community offices. We’ve got bases, where we are, where midwives work from bases in the
community. So we’ve sent posters out to the community offices, and information leaflets. So there’s
education for the women antenatally, that there is a trial running at [site X] and that the information’s
there should they want to read it.
I
Finally, when prompted, most staff members agreed that although explicitly informing all pregnant women
about the GOT-IT trial may be neither feasible nor acceptable, triaging antenatal information giving,
so that information about the study is targeted at women who have previously had a retained placenta,
might be a good idea and is a more acceptable use of resources:
Interviewer: What do you think about sort of targeting those women [with previous retained placenta]
in particular?
J: Oh yeah, absolutely. I think that’d be something that would definitely work well for women that are
aware of it, they know what it worked out to be, because they have got that fear . . . So, I think it
would definitely be great to target those kind of women that have had that previous experience
because they know about it and they know that there’s an increased risk. Because there is, I mean,
I’ve had a couple of ladies myself that had had previous retained placentas and this was them again
holding on to their placenta, so for whatever reason it just doesn’t come away from the wall.
In one site the staff reported that women who had previously had a retained placenta had been triaged to
receive trial information on an ad hoc basis, and this had been well received by the women concerned:
If women have had a retained placenta before we do warn them that it might happen again.
We haven’t gone down the lines of talking to them about GOT-IT formally but it certainly has been
mentioned informally. I would include myself in that because I have, when we first started I came
across somebody and she was very happy with the study but of course she didn’t have a retained
placenta but that’s just a one-off story, but informally that goes on but we haven’t formalised that.
Dr H
Support for future recruitment
None of the staff involved in recruitment in the pilot phase identified themselves as requiring further
support for recruitment/consenting. Indeed, all of those whom we interviewed were very positive about the
support they had received from their local research teams. However, the research midwives who were
interviewed identified a number of practical strategies (tips and pointers) that they had devised to improve
trial delivery and, thus, indirectly support trial recruitment. These were collated and a training resource to aid
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implementation of the trial in new sites was developed [see Microsoft PowerPoint® (Microsoft Corporation,
Redmond, WA, USA) slides accessible at www.journalslibrary.nihr.ac.uk/programmes/hta/122901/#/)].
Research question 6
Getting the trial up and running and keeping it going
Although the rollout of the GOT-IT trial across the pilot sites did not generate any trial-specific issues for
staff, implementing the trial took local research teams by surprise in a few of the pilot sites. The GOT-IT
trial was the first postpartum trial that some sites had been involved with, and relying on clinical staff to
recruit and consent women was seen as a major issue for the research midwives and local principal
investigators:
The hardest bit’s probably retained placenta can happen any time 24–7 and we’re only here you know
during office hours. So we are having to rely on the clinical staff that have already got a lot of things
to remember to think about GOT-IT.
Research A
I think difficult because it’s not the midwives recruiting. And all the studies I’ve worked it’s always
been me doing the recruitment. Whereas this has been different because there’s a lot of training the
doctors up. And, you know, letting them know about the study. And obviously because it’s quite a big
unit there’s a lot of doctors to get trained up. So that’s been different. We’re not the ones actually
doing the recruitment. And then so a lot of it’s been sort of chasing. I know a lot of it’s been chasing
missing data and things that the doctors have missed out really. And sort of following up which
women they were, if we’ve sort of lost track of some of them. So it’s been different to the other
studies I’ve worked on.
Research F
Requiring busy labour ward staff to deliver the trial was described as needing a great deal of forward
planning and training, particularly in sites with bigger delivery units in which a large number of staff needed
to be trained. To facilitate this training, the trial office developed a trial-specific good clinical practice light
training package. Compared with full good clinical practice training, which normally takes a minimum of
6 hours, the good clinical practice light package was designed to be completed in < 30 minutes. The training
package comprised slides, a protocol synopsis and a summary of the core principles of good clinical practice.
The good clinical practice light package was designed so that labour ward staff could complete it online in
their own time or it could be delivered face to face by the research midwives. Staff completing the training
online were required to complete and score 100% in a multiple-choice test to provide evidence that they
had completed the package and learned from its content. The package was formally risk assessed by the
trial’s sponsor and was deemed to fulfil the training requirements required by the Medicines and Healthcare
products Regulatory Agency for clinical staff to recruit to a drug trial. It was hoped that sites would be able
to use this more focused, shorter good clinical practice package to facilitate rapid, comprehensive training of
clinical staff.
The level of good clinical practice that staff in individual trusts need to undertake is determined by the
local research and development departments. In two out of the eight pilot sites, the local research and
development departments required their staff to undergo full as opposed to good clinical practice light
training. In a further site, the initial approval to use good clinical practice light was withdrawn. This
decision was subsequently overturned after discussions with the local research and development director.
In practice, in the pilot trial, the requirement for staff to undertake full as opposed to good clinical practice
light training delayed the recruitment in only one out of the eight sites. The requirement to ensure that
staff had the locally approved level of good clinical practice training, were familiar with the specific trial
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processes for the GOT-IT trial and had signed the delegation log delegating them to recruit to the trial
presented a significant logistical challenge for the research midwives:
So that was a whole new area that I’d never dealt with before, we’ve never had the sheer amount of
doctors that I’ve had to do the training with for this study that I’ve had to do with other studies . . .
it’s been a bit of a hard slog, I’ll be honest . . . I mean, it was tough going round and finding them all
but now I’ve kind of done that bit it’s OK . . . it was easier than what I thought it was going to be.
Research J
A few things made staff training at larger sites more problematic. First, because of the larger numbers,
the research midwives were generally less familiar with clinical staff. Second, these sites also used more
locums creating a continuing need for good clinical practice training. Finally, larger sites have a greater
volume of ongoing and/or competing research studies at any one time. Thus, although smaller sites may
have fewer potential recruits, the trial was reportedly easier to set up in these locations as there were
fewer doctors/midwives to train and the research midwives, particularly those who also worked clinical
shifts, already knew most of them:
Interviewer: So how has it been training the staff?
Research H: Well, like any training it’s hard to find time to really engage with staff without being
interrupted. So you’re kind of – thankfully research midwives and myself are both clinical midwives as
well. So I think that has benefited this trial. Because if it is quiet on the unit you can badger them. But
obviously, they’re like kids, they’ve only got a short time span that you try to get the most important
things across to them because, you know, they’ve got other things.
The research midwives at all sites, but particularly the larger sites, talked about the strategies that they
had employed to ensure that eligible staff received the good clinical practice that their local trust required
them to have prior to recruiting to the trial. For the research midwives who delivered face-to-face training,
these strategies included catching medical staff in quiet moments, using a GOT-IT champion (see below)
to recruit and train staff, giving talks in educational sessions, e-mailing newly recruited doctors in advance
of them starting their rotation and getting the local principal investigator to encourage individuals to
complete training online or attend for face-to-face training.
Delivering the GOT-IT trial involves more than just ensuring that medical staff are good clinical practice trained,
familiar with the trial processes and on the delegation log. Midwives who look after women during the birth
are often the first health professionals to become aware that there is a retained placenta. Although midwives
cannot assess eligibility for the trial and prescribe the study drug, they can refer women to medical staff so
that they can formally consider their eligibility for trial entry. If this referral does not occur, potentially eligible
women may not be given the opportunity to consent to the trial. The research midwives therefore talked
about how they needed to engage all labour ward staff members and make them aware of the trial and its
eligibility criteria. Thus, in addition to talking about the trial with all ward staff and making sure that the GOT-IT
trial was raised in daily safety briefs, the research midwives described how they tried to increase the visibility
of the trial on the ward by fly posting on delivery suite walls, triage area walls, in tea-making areas, near the
drug cupboard on the labour ward and, most effectively, on toilet doors. In addition, in many sites GOT-IT
flow charts and summary sheets were pinned to labour ward walls and placed in or near the drugs cupboard:
I put laminated summary sheets up for GOT-IT as well so it’s just a matter of them peeling it off the
wall and giving the summary sheet to the woman to read.
Research J
In some sites all trial materials (i.e. paperwork, checklists for filling in paperwork and trial drugs) were packaged
up together and put in easily visible and accessible places (i.e. the drug cupboard) so that staff awareness was
maintained and they could quickly and easily find the trial materials and complete them correctly.
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As retained placenta is a relatively rare occurrence, sites may not randomise for weeks at a time and this
gives research midwives the unenviable task of keeping the GOT-IT trial fresh in people’s minds. A number
of strategies were reported, such as broadcasting new randomisations at the site, issuing rewards to
recruiting staff, issuing GOT-IT pens, issuing sticky notes and issuing certificates to add to training portfolios:
I think getting a certificate is actually quite useful for your portfolio and things, to say that you’ve been
involved in clinical trials or whatever.
Dr B
And each member of staff who’s been involved so far they’ve all had their certificate printed and a bit
of a fuss made really. And they seem to be really quite excited. And they’ll ring me up, oh got another
case for you. And they seem to be quite excited about process and everybody wants one. Everybody
wants to get a case so they can have the certificate.
M
In some sites, the first person to be randomised received a bunch of flowers or perfume from the staff
and in one site the principal investigator had provided money for John Lewis vouchers prizes (John Lewis
Partnership plc, London, UK) and those who had randomised women were entered into a monthly draw.
Finally, research midwives used incentives in the form of edible treats for staff – ‘GOT-IT’ sweets, biscuits
and tea.
In addition to publicising recent randomisations in individual sites, the research midwives and trial office also
kept staff up to date with general trial progress at departmental meetings and through trial newsletters
and e-mails. The research midwives also publicised overall recruitment rates across pilot sites to encourage
inter-site competition, a strategy that some said might backfire if your site does not recruit too well.
Although all of these strategies were seen as effective, the research midwives said that having a continuing
physical presence on the ward was essential for maintaining clinical staff awareness of the need to recruit to
the GOT-IT trial. All the research midwives said that they made a great effort to go onto the labour ward/
delivery suite and talk about the GOT-IT trial whenever they could:
It’s keeping visible on the delivery suite and going up there frequently, making staff feel appreciated
for doing it as well. And not just leaving it to them and saying, right here you are, you do this. You
get on wi’ it. Ring me when you’ve got one. It’s like involving them all the time, giving them the
certificates, making them feel they’ve done something deserving credit really.
Research M
I make sure that I am visible in in the areas every day that I’m in work, and I think just, you know,
walking through labour ward and saying hi to people helps keep the profile going.
Research A
It was suggested that the profile of the trial could be maintained most effectively by having a GOT-IT
champion at every site. Dr B reflected on the important role played by the principal investigator in their site
in keeping the GOT-IT trial to the forefront of staff awareness:
We’ve obviously got the advantage of having PI [principal investigator] in the department. So, you know,
she’s a constant reminder about GOT-IT. There are GOT-IT pencils I think . . . I guess you just need
somebody like principal investigator at every place, don’t you? But you must have to have – will you not
have a – you know a co-ordinator at each site or will that not happen? If you have somebody that’s the
GOT-IT champion in each hospital and they’ll chat to people about it and keep it in everybody’s mind.
Cause it is having somebody physically around that every so often brings GOT-IT up in conversation that
keeps reminding you.
Dr B
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In another site, a junior doctor had been assigned the responsibility of championing the trial; alongside the
research midwives they were responsible for ensuring that the staff were good clinical practice trained and
keeping the GOT-IT trial at the forefront of people’s minds. The idea of appointing a GOT-IT champion for
each site from the local medical team or senior midwifery team was endorsed by the implementation
group at their meeting in May 2015.
Debriefing following trial participation
As noted above, women who had a postpartum complication (including postpartum haemorrhage) spoke
of their distress and worry that this may have been caused by study participation.26 These women said
that they would value, or had valued, the opportunity to discuss their experience with clinical/research
staff. Staff agreed that offering all women an opportunity for debriefing after the trial was a good idea as
it helps them to understand what had happened and gives them an opportunity to ask further questions,
particularly when they have experienced postpartum complications. In most cases, research midwives said
that they had debriefed women as a matter of course before they left the wards. Clinical staff in other
sites noted that the patient pathway within their trust already included a debriefing session in the event of
birthing interventions/postpartum complications.26 In one site, the local principal investigator said that in
addition to the clinical team who would routinely debrief women following a postpartum complication,
she would try to visit any woman who had experienced complications following randomisation to the
GOT-IT study:
If anybody has a major postpartum haemorrhage obviously, and they’re in this study I will go and
speak – you know show my face as well if I’m around. Obviously, if it happens on a Friday and I’m not
on that weekend . . . it might be that they go home. I can’t promise that I could do it with everyone,
because I might not be there. I might be on leave, but if I’m aware and I’m there I’ll definitely go
speak to them and just say: ‘have you got any’ – is that alright, by the way?
Dr I
Implementation: feedback of findings
As indicated earlier, the study’s implementation group was brought together for a face-to-face meeting
soon after completion of the trial’s pilot phase. This meeting was held in Edinburgh on 14 May 2015
and was chaired by Dr Claire Snowdon, a qualitative perinatal trials expert who is also a member of the
trial’s steering group. Those attending included representatives from the eight pilot sites, Dr Fiona Denison
(chief investigator for the GOT-IT trial) and a patient representative.
The meeting comprised a 45-minute PowerPoint presentation delivered by Julia Lawton and Nina Hallowell
that covered all of the key issues and findings presented above. This was followed by a 30-minute facilitated
discussion to develop a series of recommendations that could be implemented during the main phase of
the trial to maintain successful recruitment, optimise and sustain effective trial delivery and maximise
opportunities for gaining full informed consent.
The final document, containing a summary of the recommendations of the implementation group, is
contained in Box 1, along with how the recommendations were implemented in practice. The qualitative
research team also compiled a set of training slides (see www.journalslibrary.nihr.ac.uk/programmes/hta/
122901/#/) for use as a training resource when new sites came on board in the main trial. This training
pack included implementation group recommendations and a number of tips and practical strategies
developed by the pilot sites for optimising successful trial delivery. The trial manager circulated this training
resource to all the sites in the main trial.
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BOX 1 Implementation group’s recommendations
Recommendation 1
The implementation group recognised that the qualitative team had not been able to interview women who
had received antenatal information about the trial because the women recruited during the pilot would not
have had opportunities to be exposed to this information.
Recommendation 2
The implementation group discussed the findings from the interviews with women in which they described the
potential benefits of trial information being given during the antenatal period. These were weighed against the
views of staff interviewed in the study, who were more ambivalent about providing information to women
during the antenatal period. The implementation group also noted the cost and logistical implications of
following Vernon et al.’s35 recommendation for giving all pregnant women in the trial sites information leaflets.
Implementation: the local challenges of informing potential trial participants and potential solutions were
discussed at site initiation visits and at the regular monthly research midwives’ teleconferences. The latter were
organised and led by the research midwives based in Edinburgh.
Recommendation 3
The implementation group recommended that the pathway to be used in the main trial should draw on the
principles of the pathway developed by Vernon et al.,35 but be ‘scaled down’. It was proposed that information
about the trial should be displayed in settings in which women receive their antenatal care in the form of
posters and leaflets.
It was also agreed that these documents should contain clear information about how women could access
further information should they wish to do so; for instance, by providing contact details of trial staff and links
to websites (GOT-IT or local trust websites) containing more information about the trial and about retained
placentas). The potential to use social media such as Twitter (Twitter, Inc., San Francisco, CA, USA) and
Facebook (Facebook, Inc., Menlo Park, CA, USA) was also highlighted. It was suggested that the proposed
method of information delivery would meet the needs of women who are ‘information hungry’ while not
overburdening those who are not. The committee noted that any changes or additions to existing
documentation would require ethics approval.
Implementation: sites were encouraged to develop local solutions for information dissemination to women.
Examples of good practice were discussed and shared at the midwives’ teleconferences.
Recommendation 4
The implementation group recommended that those women who are identified as being at increased risk of
having a retained placenta (e.g. because of having had one previously) should, when possible, be targeted
during the antenatal period and these individuals should be given a trial information sheet.
Implementation: this particular issue was highlighted and regularly fed back to local sites via the monthly
midwives’ teleconferences.
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Recommendation 5
Some women experienced a postpartum haemorrhage and questioned if this was related to their participation
in the trial or if it was because they had a retained placenta. The implementation group recognised that it
was good clinical practice for all women with a retained placenta who had a postpartum haemorrhage to be
debriefed about their experience. In addition to women with a retained placenta and postpartum haemorrhage,
the implementation group recognised the importance of offering a specific debriefing session on an as-needed
basis to trial participants who want to know more about retained placentas, the trial and its procedures so they
can make sense of their birth experience. Ideally, this should take place before they leave hospital. If this is not
possible, follow-up should be provided, although some staff members of the implementation group noted that
it is ethically and logistically more difficult to contact women after they are discharged. Therefore, it was advised
that local solutions to this problem should be developed.
Implementation: local units were encouraged to develop solutions for this. When practical, the local research
midwives tried to debrief all participants before they left hospital.
Recommendation 6
The implementation group agreed that women should be thanked for their participation and that, ideally, this
should be done when the research midwives visit them on the wards. If this is not possible, women should be
sent a thank-you letter/card (see www.journalslibrary.nihr.ac.uk/programmes/hta/122901/#/).
Implementation: in addition to face-to-face debriefs, sites were provided with thank-you cards.
Recommendation 7
It was observed that in certain sites the appointment of a GOT-IT champion from the clinical staff had been
very useful in promoting the trial amongst clinical staff. It was suggested that all sites might benefit by signing
up a GOT-IT champion (e.g. junior or senior doctor) to support the research midwives. This person should be
awarded a certificate to acknowledge their work (designed and issued by the trial office) and their role
publicised locally (see www.journalslibrary.nihr.ac.uk/programmes/hta/122901/#/ for additional information).
Implementation: sites were provided with certificates to give to local site champions. Local sites were also
encouraged to thank all those who recruited to the trial. Some sites set up local walls of fame or competitions
to encourage trial recruitment.
Recommendation 8
The implementation group supported the qualitative research team’s proposal to compile a list of slides for use
in the induction of future trial sites. These would list practical suggestions and solutions developed in the pilot
sites for facilitating trial delivery.
Implementation: the slides were circulated to new sites and key messages were embedded within the slides
used for site initiation.
BOX 1 Implementation group’s recommendations (continued )
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Concluding comments
All objectives of the nested qualitative study were achieved and all of the original research questions
answered. As well as the published papers, the qualitative study led to the generation of two significant
outputs for use in the main trial: the recommendations from the implementation group and the staff
training resource. The implementation group’s recommendations were used to support delivery of the
GOT-IT trial to the full site list.
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Chapter 4 Participant baseline characteristics
Trial recruitment
Recruitment into the trial was between 13 October 2014 and 26 July 2017 and was followed up to
September 2017. Figure 2 shows the trajectory of the recruitment from all centres. In total, 1107 participants
were recruited from 29 UK NHS hospitals (Table 3) for treatment of retained placenta. All centres recruited
to both interventions with 543 randomised to GTN and 564 randomised to placebo.
Participant flow
The Consolidated Standards of Reporting Trials (CONSORT) flow diagram for the trial is shown in Figure 3.
Of the 1671 patients screened, 1188 were eligible. For the 483 patients who were excluded, 353 were
ineligible, 63 declined, 60 were missed and it was not appropriate to approach 7 patients. Of the 63 patients
who declined, 22 (34.9%) did not provide a reason and 15 (24.8%) preferred to go straight to theatre.
The main reason why patients were missed was because there were no medical staff on duty that had
signed the delegation log. Further details of the reasons for patients being excluded are provided in Table 4.
Three participants were excluded post randomisation (two in the GTN group and one in the placebo group)
because the baseline observations prior to investigational medicinal product administration made them
ineligible for participation. Six participants in the GTN group and seven in the placebo group did not receive
the study drug. The reasons are detailed in Table 5.
The pre-discharge questionnaire was completed by 390 participants in the GTN group and 399 in the
placebo group. At the 6-week follow-up, 228 completed and returned the questionnaire in the GTN group
(31 did not consent to receiving the questionnaire) and 241 completed and returned the questionnaire in
the placebo group (25 did not consent to receiving the questionnaire).
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FIGURE 2 Recruitment over time.
DOI: 10.3310/hta23700 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 70
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Denison et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
TABLE 3 Recruitment by centre
Centre
Randomised (N= 1107),
n (%)
Treatment group, n (%)
GTN (N= 543) Placebo (N= 564)
Royal Infirmary of Edinburgh 92 (8.3) 45 (8.3) 47 (8.3)
Queen Elizabeth University Hospital 24 (2.2) 11 (2.0) 13 (2.3)
St Mary’s Hospital 122 (11.0) 64 (11.8) 58 (10.3)
Royal Victoria Infirmary 42 (3.8) 20 (3.7) 22 (3.9)
Royal Preston Hospital 80 (7.2) 39 (7.2) 41 (7.3)
Warrington Hospital 45 (4.1) 21 (3.9) 24 (4.3)
Chesterfield Royal Hospital 47 (4.2) 21 (3.9) 26 (4.6)
Leighton Hospital 46 (4.2) 20 (3.7) 26 (4.6)
University Hospital of North Durham 33 (3.0) 16 (2.9) 17 (3.0)
West Middlesex University Hospital 28 (2.5) 14 (2.6) 14 (2.5)
Stoke Mandeville Hospital 55 (5.0) 27 (5.0) 28 (5.0)
Furness General Hospital 10 (0.9) 6 (1.1) 4 (0.7)
University Hospital Southampton NHS
Foundation Trust
47 (4.2) 24 (4.4) 23 (4.1)
Bolton NHS Foundation Trust 48 (4.3) 24 (4.4) 24 (4.3)
Sunderland Royal Hospital 86 (7.8) 42 (7.7) 44 (7.8)
Oxford University Hospitals 45 (4.1) 23 (4.2) 22 (3.9)
Nottingham University Hospitals NHS Trust Queen’s
Medical Centre
28 (2.5) 13 (2.4) 15 (2.7)
Nottingham University Hospitals NHS Trust City
Campus
37 (3.3) 18 (3.3) 19 (3.4)
East Lancashire Hospital NHS Trust Burnley General
Hospital
28 (2.5) 13 (2.4) 15 (2.7)
Ashford and St Peter’s Hospitals NHS Trust 17 (1.5) 9 (1.7) 8 (1.4)
North Tees and Hartlepool Hospitals NHS
Foundation Trust
19 (1.7) 10 (1.8) 9 (1.6)
South Tees Hospital NHS Foundation Trust James
Cook Hospital
17 (1.5) 9 (1.7) 8 (1.4)
Countess of Chester Hospital NHS Foundation Trust 18 (1.6) 8 (1.5) 10 (1.8)
Darlington Memorial Hospital 8 (0.7) 4 (0.7) 4 (0.7)
York Teaching Hospital 21 (1.9) 9 (1.7) 12 (2.1)
The Royal Berkshire Hospital 16 (1.4) 8 (1.5) 8 (1.4)
Milton Keynes University Hospital 20 (1.8) 12 (2.2) 8 (1.4)
Shrewsbury and Telford Hospital NHS Trust 18 (1.6) 8 (1.5) 10 (1.8)
Frimley Park Hospital 10 (0.9) 5 (0.9) 5 (0.9)
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Patients screened
(n = 1671)
Eligible patients
(n = 1188)
Randomised
(n = 1107)
GTN
(n = 543)
Postrandomisation exclusion
(n = 2)
            Not eligible
            (n = 483)
• Ineligible, n = 353
• Declined,a n = 63
• Missed, n = 60
• Not appropriate, n = 7
             Not randomised
           (n = 81)
• Became ineligible, n = 8
• Placenta was delivered, n = 10
• Declined, n = 63
• Received GTN, n = 535
• Did not receive GTN, n = 6
6-weeks follow-up
• Case report form, n = 541
• Patient questionnaire, n = 228
• No consent, n = 31
Placebo
(n = 564)
Postrandomisation exclusion
(n = 1)
• Received placebo, n = 556
• Did not receive placebo, n = 7
6-weeks follow-up
• Case report form, n = 563
• Patient questionnaire, n = 241
• No consent, n = 25
Pre discharge
• Case report form, n = 563
• Patient questionnaire, n = 399
Pre discharge
• Case report form, n = 541
• Patient questionnaire, n = 390
FIGURE 3 The CONSORT flow diagram. a, Declined refers to women with retained placenta who declined trial
participation before their eligibility criteria were able to be checked.
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Baseline characteristics
The participants’ baseline characteristics are shown in Table 6 and are balanced between the two treatment
groups. The mean age was 31 years in both groups and the majority of participants were white (86.5% in
the GTN group and 86.5% in the placebo group). The mean systolic and diastolic blood pressure in the
GTN group was 123.8 mmHg and 73.3 mmHg, respectively, and in the placebo group was 124.6 mmHg
and 75.1 mmHg, respectively. The mean heart rate was 84.6 b.p.m. for participants in the GTN group and
84.7 b.p.m. for participants in the placebo group. Over half the participants had had a previous pregnancy
(GTN group, 57.5%; placebo group, 57.4%).
TABLE 4 Description of non-eligible participants
Reason for being non-eligible
Number of
participants % of total
Reasons for ineligibility 353
Did not meet eligibility criteria 335 94.9
Clinical reasons 12 3.4
Placenta delivered before eligible criteria could be checked 6 1.1
Reasons for declining to take part 63
No reason given 22 34.9
Preferred to go straight to theatre 15 23.8
Did not wish to take part 11 17.5
Did not want to participate in research 5 7.9
Randomisation process 2 3.2
Other 8 12.7
Reasons for missing participants 60
No medical staff on duty that were on the delegation log 1 1.6
No reason given 40 66.7
Recruitment on halt 15 25.0
Drugs not available 4 6.7
TABLE 5 Reasons why study drug was not given
Reasons why study drug was not given
Treatment group
GTN (N= 541) Placebo (N= 563)
Study drug not given, n (%) 6 (1.1) 7 (1.2)
Reasons
Placenta was delivered before drug was administered 0 4
Blood pressure was ≤ 100mmHg 2 1
Blood pressure was ≤ 100mmHg and heart rate was > 119 b.p.m.
when rechecked
2 0
Bleeding 1 1
Heart rate increased 0 1
Medical team misinterpreted 30-to 60-minutes criteria and wrongly assumed
spray was given
1 0
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TABLE 6 Baseline characteristics
Baseline characteristics
Treatment group
GTN (N= 541) Placebo (N= 563)
Age (years), mean (SD); n 30.6 (5.5); 541 30.8 (5.1); 563
Body mass index (kg/m2), mean (SD); n 25.8 (5.4); 526 25.4 (5.2); 548
Smoker, n (%)
Current 75 (13.9) 77 (13.7)
Ex-smoker 101 (18.7) 98 (17.4)
Never 350 (64.7) 376 (66.8)
Missing 15 (2.8) 12 (2.1)
Alcohol use in pregnancy, n (%)
Yes 19 (3.5) 18 (3.2)
No 505 (93.3) 521 (92.5)
Missing 17 (3.1) 24 (4.3)
Ethnicity, n (%)
White 468 (86.5) 487 (86.5)
Asian 38 (7.0) 41 (7.3)
Black 7 (1.3) 8 (1.4)
Mixed 5 (0.9) 6 (1.1)
Chinese 5 (0.9) 6 (1.1)
Other 5 (0.9) 6 (1.1)
Missing 13 (2.4) 9 (1.6)
Blood pressure (mmHg), mean (SD); n
Systolic 123.8 (12.8); 538 124.6 (12.6); 559
Diastolic 73.3 (10.2); 535 75.1 (10.1); 559
Heart rate (b.p.m.), mean (SD); n 84.6 (13.0); 539 84.7 (12.9); 559
Temperature (°C), mean (SD); n 36.8 (0.5); 513 36.9 (0.4); 534
Haemoglobin level (g/dl), mean (SD); n 12.2 (1.3); 468 12.3 (1.4); 478
Previous pregnancy, n (%) 311 (57.5) 323 (57.4)
Previous retained placenta, n (%) 48 (15.4) 57 (17.6)
Previous placenta praevia/accreta, n (%) 4 (1.3) 1 (0.3)
SD, standard deviation.
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Chapter 5 Outcomes and results
Primary outcome
The trial did not stop early at any of the interim analysis stages; therefore, the analysis was performed on
1104 participants. The proportion of participants in whom the placenta remained undelivered or required
manual removal of placenta within 15 minutes was similar in both groups [n = 505 (93.3%) in the GTN
group and n = 518 (92.0%) in the placebo group] (Table 7). Adjusting for multiple looks at the data, there
was no difference in the primary clinical outcome between the two groups [odds ratio (OR) 1.01, 95% CI
0.98 to 1.04; p = 0.393].
Table 8 provides details of the method of removing the placenta. For participants that delivered the
placenta within 15 minutes, 86.1% of placentae were delivered by controlled cord traction in the GTN
group and 86.7% in the placebo group. For the participants for whom the placenta was delivered after
15 minutes, the majority of participants underwent manual removal of placenta (GTN group, 80.6%;
placebo group, 80.5%).
TABLE 8 Method of placenta removal
Method of placenta removal
Treatment group, n/N (%)
GTN (N= 541) Placebo (N= 563)
Placenta delivered within 15 minutes
Spontaneous 5/36 (13.9) 6/45 (13.3)
Controlled cord traction 31/36 (86.1) 39/45 (86.7)
Placenta delivered after 15 minutes
Spontaneous 13/505 (2.6) 16/518 (3.1)
Controlled cord traction 83/505 (16.4) 84/518 (16.2)
Manual removal of placenta 407/505 (80.6) 417/518 (80.5)
Othera 1/505 (0.2) 1/518 (0.2)
Unknownb 1/505 (0.2)
a Suction removal; removed with uterus at hysterectomy.
b Participant was discharged with placenta still inside.
TABLE 7 Placenta remaining undelivered 15 minutes post study treatment and/or requiring manual removal of
placenta within 15 minutes of treatment because of safety concerns
Time
Treatment group, n (%)
OR 95% CI p-valueGTN (N= 541) Placebo (N= 563)
Delivered within 15 minutes 36 (6.7) 45 (8.0)
Undelivered within 15 minutes 505 (93.3) 518 (92.0) 1.01 0.98 to 1.04 0.393
The analysis was adjusted for multiple looks at the data.
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Figure 4 shows the stopping boundaries and the pathway of the group-sequential analysis. At each interim
look a test statistic based on the accumulated data determined whether or not the trial should be stopped
based on whether or not it crossed any of the boundaries (stopping for futility only at the third interim
look and at the final analysis). Based on the trial results, we did not cross any of the boundaries at the
interim analyses and proceeded to the final analysis.
Blood loss between the administration of the study drug and the transfer to a postnatal ward (or other
clinical area) is shown in Table 9. Blood loss was < 500 ml in 44.3% of the GTN group and in 44.5% of
the placebo group. There was a blood loss of > 1000 ml in 22.2% of participants in the GTN group and
in 15.5% of the placebo group. There was no difference in the primary safety outcome of blood loss
between the groups (proportional OR 1.14, 95% CI 0.88 to 1.48; p = 0.314).
Patient satisfaction and side-effect profile before and at 6 weeks are shown in Table 10. There was no
evidence of a difference in the primary patient-sided satisfaction outcome of recommending the study
drug to a friend/relative pre discharge (OR 0.87, 95% CI 0.62 to 1.22; p = 0.411) and at 6 weeks
(OR 1.02, 95% CI 0.66 to 1.56; p = 0.941). For the primary patient-sided safety outcome, feeling sick pre
discharge and at 6 weeks both showed no evidence of a difference between the two groups. Palpitations/
heart racing showed evidence of a difference at pre discharge in favour of the placebo group (OR 2.60,
95% CI 1.40 to 4.84; p = 0.003); at 6 weeks there was no evidence of a difference.
TABLE 9 Blood loss between administration of study drug and transfer to a postnatal ward or other clinical area
Blood loss (ml)
Treatment group, n/N (%)
OR 95% CI p-valueGTN (N= 41) Placebo (N= 563)
< 500 238/537 (44.3) 249/560 (44.5)
500–1000 180/537 (33.5) 224/560 (40.0)
> 1000 119/537 (22.2) 87/560 (15.5) 1.14 0.88 to 1.48 0.314
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FIGURE 4 Stopping boundaries and pathway of group-sequential analysis. Black, efficacy boundaries; green, futility
boundaries; blue, test statistic.
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Secondary outcome
The secondary clinical outcomes are shown in Table 11. There was no evidence of a difference of a > 15%
fall in haemoglobin level between recruitment and the first postnatal day between the two groups. Participants
randomised to the GTN group were more likely than those in the placebo group to have a fall in systolic
blood pressure, diastolic blood pressure and/or an increase in heart rate (OR 4.90, 95% CI 3.73 to 6.42;
p < 0.001). Participants were also more likely to require a blood transfusion between time of delivery and
discharge from hospital if they had received GTN (OR 1.53, 95% CI 1.04 to 2.25; p = 0.033). There was no
evidence of a difference between the groups for maternal pyrexia time from randomisation to delivery of
placenta, manual removal of placenta in theatre, general anaesthesia and sustained uterine relaxation.
Subgroup analysis
As there was a low event rate in the clinical primary outcome, the event rate in the subgroups was too low
to perform the planned subgroup analysis.
TABLE 10 Patient satisfaction and side-effect profile before discharge and at 6 weeks
Patient satisfaction and
side-effect profile
Treatment group, n/N (%)
OR 95% CI p-valueGTN (N= 541) Placebo (N= 563)
Recommend study drug to a friend/relative?
Pre discharge
No 94/382 (24.6) 85/388 (21.9)
Yes 288/382 (75.4) 303/388 (78.1) 0.87 0.62 to 1.22 0.411
6 weeks
No 55/221 (24.9) 60/238 (25.2)
Yes 166/221 (75.1) 178/238 (74.8) 1.02 0.66 to 1.56 0.941
Feeling sick
Pre discharge
No 299/377 (79.3) 323/384 (84.1)
Yes 78/377 (20.7) 61/384 (15.9) 1.37 0.94 to 1.99 0.101
6 weeks
No 180/211 (85.3) 206/232 (88.8)
Yes 31/211 (14.7) 26/232 (11.2) 1.40 0.80 to 2.47 0.239
Palpitations/heart racing
Pre discharge
No 332/368 (90.2) 360/375 (96.0)
Yes 36/368 (9.8) 15/375 (4.0) 2.60 1.40 to 4.84 0.003
6 weeks
No 186/200 (93.0) 215/225 (95.6)
Yes 14/200 (7.0) 10/225 (4.4) 1.62 0.70 to 3.73 0.258
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Adverse events
In total, there were 52 SAEs during the trial, with all participants who experienced a SAE only experiencing
one event [GTN group, n = 27 (5.0%); placebo group, n = 25 (4.4%)]. Most of the events required
hospitalisation (GTN group, n = 24; placebo group, n = 24). The severity of the events was mainly moderate
(GTN group, n = 16; placebo group, n = 16) with three events in the placebo group being life-threatening
(two were postpartum haemorrhage and one was anaphylaxis due to suxamethonium chloride). Most of
the SAEs were due to postpartum haemorrhage (GTN group, n = 23; placebo group, n = 16). The only other
SAEs of note were retained products of conception (GTN group, n = 1; placebo group, n = 3). Further details
are provided in Table 12.
TABLE 11 Secondary clinical outcomes
Clinical outcome
Treatment group
Effect sizea 95% CI p-valueGTN (N= 541) Placebo (N= 563)
> 15% fall in haemoglobin, n/N (%)
No 160/414 (38.6) 180/421 (42.8)
Yes 254/414 (61.4) 241/421 (57.2) 1.19 0.93 to 1.52 0.175
Time from randomisation to delivery of
placenta (minutes), mean SD; n
12.1 (7.3); 539 12.2 (7.0); 561 0.19 –0.94 to 0.55 0.601
Manual removal of placenta in theatre, n/N (%)
No 141/540 (26.1) 152/563 (27.0)
Yes 399/540 (73.9) 411/563 (73.0) 1.05 0.80 to 1.36 0.736
Need for earlier than planned manual removal of placenta, n/N (%)
No 407/416 (97.8) 420/431 (97.4)
Yes 9/416 (2.2) 11/431 (2.6) 0.84 0.30 to 2.35 0.746
Fall in systolic or diastolic blood pressure of > 15mmHg and/or increase in heart rate of 20 b.p.m., n/N (%)
No 208/531 (39.2) 413/544 (75.9)
Yes 323/531 (60.8) 131/544 (24.1) 4.90 3.73 to 6.42 < 0.001
Blood transfusion, n/N (%)
No 472/533 (88.6) 508/551 (92.2)
Yes 61/533 (11.4) 43/551 (7.8) 1.53 1.04 to 2.25 0.033
General anaesthesia, n/N (%)
No 390/438 (89.0) 398/443 (89.8)
Yes 48/438 (11.0) 45/443 (10.2) 1.09 0.66 to 1.80 0.741
Maternal pyrexia, n/N (%)
No 516/527 (97.9) 530/551 (96.2)
Yes 11/527 (2.1) 21/551 (3.8) 0.54 0.26 to 1.11 0.092
Sustained uterine relaxation, n/N (%)
No 460/528 (87.1) 482/550 (87.6)
Yes 68/528 (12.9) 68/550 (12.4) 1.05 0.76 to 1.44 0.771
SD, standard deviation.
a Effect sizes are ORs apart from time from randomisation to delivery of placenta, which is mean difference.
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Adverse events are shown in Table 13. There were 430 events of which 352 participants (GTN group,
n = 167; placebo group, n = 185) had an event. The majority were unrelated, of mild severity and were
expected. There was a variety of different AEs, most were postpartum haemorrhage (GTN group, n = 173;
placebo group, n = 175), hypotensive (GTN group, n = 6; placebo group, n = 21) and sepsis (GTN group,
n = 7; placebo group, n = 10).
TABLE 12 Serious adverse events
SAEs
Treatment group, n (%)
GTN (N= 541) Placebo (N= 563)
Number of SAEsa 27 (5.0) 25 (4.4)
Hospitalisation 24 24
Life-threatening 0 3
Other significant medical event 6 2
Severity of event
Mild 7 4
Moderate 19 16
Severe 1 5
Event due to progression of underlying disease
Yes 5 2
No 21 23
Not applicable 1 0
Event due to a lack of efficacy of investigational medicinal product
Yes 1 0
No 25 25
Not applicable 1 0
Details of SAE
Postpartum haemorrhage 23 16
Retained products of conception 1 3
Endometritis 1 0
Sepsis 0 1
Chest infection 1 0
Gall stone pancreatitis 1 0
Anaphylaxis due to suxamethonium 0 1
Escherichia coli and Clostridium difficile infection 0 1
Elevated blood pressure 0 1
Emergency hysterectomy 0 1
Postdural headache 0 1
a Participants experienced only one SAE.
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TABLE 13 Adverse events
AEs
Treatment group, n
GTN (N= 541) Placebo (N= 563)
Number of participants with an AE 166 185
Number of AEs 204 226
Causality
Unrelated 53 54
Possibly related 151 172
Severity
Mild 144 147
Moderate 57 72
Severe 3 7
Expectedness
Expected 166 184
Unexpected 38 41
Not applicable 0 1
Details of AEs
Postpartum haemorrhage 173 175
Hypotensive 6 21
Sepsis 7 10
Tachycardia 5 6
Headache 0 4
Rise in blood pressure 4 0
Vasovagal episode 0 3
Sublingual discomfort 2 0
Uncoagulated full blood count sample 1 0
Acute cholecystitis 0 1
Constipation 1 0
Feeling dizzy 1 0
Nausea 0 1
Perineal tear 1 1
Placenta accreta 0 1
Postnatal readmission for retained products 0 1
Potential deep-vein thrombosis 1 0
Self-discharge from hospital 0 1
Vomiting 0 1
Facial rash 1 0
General anaesthetic 1 0
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Chapter 6 Resource use, costs and
cost-effectiveness
This chapter describes methods for conducting the economic analysis alongside the trial and presentsthe results in the context of the preceding clinical effectiveness and safety data. As stated in the trial
protocol, the primary economic outcome is the net incremental cost (or cost saving) to the NHS of using
GTN for the treatment of retained placenta compared with standard practice. Included in the analysis are
the costs of drug acquisition and administration, monitoring prior to delivery of the placenta or transfer
to theatre, placenta delivery and further health service resource use up to 6 weeks following delivery.
The methods for measuring and valuing the relevant resource-use data are summarised in the following
sections. Following this, results are presented by treatment allocation group alongside key primary and
secondary clinical effectiveness and safety outcomes in a cost–consequences balance sheet.
Methods
Although the cost of GTN is low, there may be further costs associated with its administration and the
monitoring and management of women thereafter. It is therefore important in the context of scarce
maternity resources to explicitly quantify the net costs (or cost savings) associated with its use. Provision
was therefore made in the GOT-IT protocol to carry out a simple cost analysis using clinical and resource-use
data collected for individual participants recruited to the trial. This analysis explicitly quantifies the difference
in mean costs between the active intervention and placebo groups.
Resource use associated with the alternative management strategies was estimated from the time of
randomisation through to 6 weeks post childbirth. This included:
1. staff time for administration of the study drug and monitoring of the patient until time of placenta
delivery or transfer to theatre for manual removal of placenta
2. resource use associated with complications arising following administration of the study drug
or placebo
3. subsequent costs associated with delivery of the placenta (either spontaneously or operatively)
4. costs associated with the postnatal stay (to discharge)
5. subsequent health service contacts potentially relating to retained products of conception up to
6 weeks post discharge.
The time from administration of the study drug to spontaneous delivery of the placenta (or the decision to
proceed with manual removal), and the incidence of complications following administration of the drug,
were collected using the trial case report forms. Information about health service use in the 6 weeks following
discharge was collected via a 6-week postnatal record check and several health service resource-use questions
were included in the participant postnatal questionnaire (also at 6 weeks). Resource use was valued using
routine sources of nationally relevant unit costs.40–44
Mean costs are summarised by treatment allocation group following the principles of intention to treat,
and the incremental cost (cost saving) associated with the use of GTN is estimated using linear regression
with cluster robust CIs to adjust for potential centre effects. The cost data is presented alongside the
primary and secondary outcome data in a cost–consequence balance sheet, indicating which strategy each
outcome favours.
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Measurement and valuation of resource-use data
The time from randomisation to delivery of placenta or transfer to theatre for manual removal of placenta
was derived from the trial case report forms and costed using the unit cost per patient contact hour for
someone on band 6.40 This multiplier includes an overhead and capital apportionment. For those not
requiring manual removal of placenta or transfer to theatre for other reasons, the remaining maternal stay
was costed using a national average bed-day cost following vaginal deliveries, applied to actual duration of
stay following delivery of the placenta. This unit cost was taken as relevant excess bed-day cost obtained
from the NHS Reference Costs 2015 to 2016.41 Because we did not have detailed data on mode of vaginal
delivery for individual patients, we applied a weighted average (by national activity levels) of the excess
bed-day costs for all health-care resource-use groups relating to normal and assisted deliveries: NZ30-34
and NZ40-44. Drug costs for GTN were also applied to those randomised to the GTN group (Table 14).42
Tables 15–17 summarise the data sources used for the costing of hospital resources (see Table 15), primary
care (see Table 16) and secondary care (see Table 17). For women who were transferred to the theatre but
did not subsequently require a manual removal of placenta, the cost of theatre resources was estimated
by applying a running cost per hour of obstetric theatre time obtained from Scottish Health Service Costs
(2016) data.43 For women requiring a blood transfusion, a unit cost per red cell unit transfused was applied,
assuming an average of two units per woman.44 For women who were transferred to theatre and received
manual removal of placenta, these episodes were costed using the NHS reference cost for such episodes.
Manual removal of the placenta maps to health-care resource-use group code NZ27Z (postnatal therapeutic
procedures).41 The unit cost for this health-care resource-use group code reflects the average cost of these
procedures across the NHS. The time and date of discharge were additionally used to estimate the overall
health-care resource-use group code-based reference cost for each manual removal of placenta episode.
The 6-week postnatal record check provided data on any readmissions to hospital deemed to be potentially
relevant to retained placenta or study drug. All readmissions were costed using appropriate health-care
resource-use group codes combined with length of stay. Finally, the postnatal patient questionnaire
provided information on participants’ use of community midwifery, health visitor and primary care services
up to 6 weeks post discharge. Reported use of these services was costed using national unit cost data.40
In addition, the questionnaire collected data on any further outpatient appointments. Outpatient attendances
were costed using the average unit price for outpatient appointments obtained from national sources.40
The questionnaire was piloted with 15 women as part of the qualitative study at Edinburgh Royal Infirmary
prior to finalisation (see Chapter 3). On the basis of these interviews, the wording of the questionnaire
was refined slightly to avoid capturing routine primary care and health visitor contacts relating to the health
of the baby. Tables 14–17 summarise the type of resource use captured and the associated sources of
measurement and valuation. All costs were expressed for the 2015–16 financial year.
TABLE 14 Identification, measurement and valuation of resource use: intervention
Resource How measured? Source of measurement Unit cost (£) Source of valuation
aCoro Nitro®
(glyceryl trinitrate)
Drug (2 × 400 µg/puff)
administered or not
From case report form –
randomisation
3.44/200-dose unit British National
Formulary42
Placebo Placebo administered
or not
From case report form –
randomisation
0 Not applicable
The costing is made on the basis of comparing GTN with no treatment.
a Manufacturer – Pharmasol Ltd, Andover, UK; marketing authorisation holder – product licence holder – Ayrton Saunders
Ltd, Moreton, UK; and distributed by Winthrop Pharmaceuticals Winthrop, Guildford, UK.
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TABLE 15 Identification, measurement and valuation of resource use: hospital resource
Resource How measured? Source of measurement Unit cost (£) Source of valuation
Monitoring of
patient by hospital
Length of time to
placenta delivery/or
time transfer to
theatre
From case report form –
clinical observation
@ 5–15 minutes
108/hour of patient
contact
Curtis and Burns40
Management by
surgical team in
theatre (for those
with spontaneous
delivery of placenta)
Length of time in
theatre
From case report form –
clinical observation
@ 5–15 minutes
667/hour Information Services
Division Scotland43
Hospital stay
(following
spontaneous
delivery of placenta)
Length of stay
(number of days)
From case report forms –
randomisation and
pre-discharge
454.86/day Health resource group
codes (NES/XSa for
NZ27Zb)41
Manual removal of
placenta
Manual removal of
placenta performed
or not
From case report form –
clinical observation
@ 5–15 minutes
Day case, 983.38;
non-elective short stay
(1 day), 1149.59;
non-elective (> 1 day),
1149.59 + (496.61 ×
number of days > 1 day)
Health resource
group codes (NZ27Zb,
OPCS R29.1c)41
a NES/XS: non-elective short stay, excess bed-days.
b NZ27Z: postnatal therapeutic procedures.
c OPCS R29.1: the OPCS Classification of Interventions and Procedures version 4 for retained placenta.45
TABLE 16 Identification, measurement and valuation of resource use: primary care
Resource How measured? Source of measurement Unit cost (£) Source of valuation
Calls Number of calls made From postnatal patient
questionnaire
7.33/10 minutes per call Curtis and Burns40
Visits Number of visits From postnatal patient
questionnaire
14.67/20 minutes per
visit
Curtis and Burns40
Health visitor calls Number of calls made
to health visitor
From postnatal patient
questionnaire
7.00/10 minutes per call Curtis and Burns40
Health visitor visits Number of health
visitor visits
From postnatal patient
questionnaire
14/20 minutes per visit Curtis and Burns40
GP visits Number of visits to
GP
From postnatal patient
questionnaire
36/9.22 minutes per
visit
Curtis and Burns40
GP calls Number of telephone
consultations with GP
From postnatal patient
questionnaire
36/9.22 minutes per call Curtis and Burns40
GP home visits Number of home
visits by GP
From postnatal patient
questionnaire
44.84/11.4 minutes per
home visit
Curtis and Burns40
TABLE 17 Identification, measurement and valuation of resource use: secondary care
Resource How measured? Source of measurement Unit cost (£) Source of valuation
Outpatient
attendance
Number of outpatient
appointments
From postnatal patient
questionnaire
136.79 per attendance Curtis and Burns40
Hospital
readmission
Length of stay
(number of days)
Case report form
completed at 6 weeks
post childbirth
Various HRG-based reference
costs39
HRG, Healthcare Resource Group.
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Analysis of cost data
Total costs were estimated for each woman enrolled in the trial as the sum of each cost element. These
are summarised by treatment allocation group (by intention to treat) and broken down into the following
categories: intervention and monitoring costs [until delivery of the placenta (non-manual removal of
placenta) or transfer to theatre], theatre costs for non-manual removal of placenta procedures, manual
removal of placenta costs, total episode costs (randomisation to discharge) and postdischarge costs
(primary and secondary care). The mean differences in cost between groups was estimated using ordinary
least squares regression. Cluster robust standard errors and CIs were implemented to account for possible
within-centre correlation. All analyses were conducted in Stata 13® (StataCorp LP, College Station, TX, USA).
Further sensitivity analysis was conducted to assess the robustness of the findings to the costing approach.
For the first sensitivity analysis [sensitivity analysis 1 (SA1)], we costed all manual removals using the
running cost per hour of obstetric theatres in Scotland43 and costed the postnatal admission using the
average bed-day cost following vaginal deliveries. For the second sensitivity analysis [sensitivity analysis 2
(SA2)], we costed manual removals using the difference between the NHS reference costs for vaginal
deliveries with (NZ32, NZ33, NZ42 and NZ43) and without (NZ30, NZ31, NZ40 and NZ41) postnatal
surgery.41
The number of missing data was very low for major cost drivers associated with the initial delivery episode
and readmissions to hospital, but substantial for postdischarge outpatient and primary care costs up to
6 weeks. Alternative assumptions about mechanisms for missing data were applied depending on the
variable; missing elements of primary care use, where participants had responded to some resource-use
questions but not others, were assumed missing not at random but because of irrelevance to the participant.
In this case, zeros were assigned. Other resource-use variables were assumed missing at random. We originally
planned to use multiple imputation to generate multiple plausible values for these missing data items,
but because data was complete for over ≈90% of the major cost drivers, this was deemed unnecessary.
The postdischarge outpatient and primary care costs up to 6 weeks formed only a very small component
of the overall costs.
Differences in costs are presented alongside the statistical comparisons of primary and secondary efficacy
and safety outcomes in the form of a cost–consequence balance sheet. This provides a summary of the
strategy favoured on cost and all the other outcomes of interest. All effects on the clinical, patient-oriented
and safety outcomes were derived as detailed in the statistical analysis section (see Chapter 5).
Results
Table 18 summarises the resource use associated with the index hospital episode, from time of randomisation
to time of discharge. There were no obvious notable differences in elements of resource use associated with
the hospital stay. Manual removal of placentae were slightly more frequent in the GTN group, as were blood
transfusions.
Table 19 summarises further secondary care resource use between discharge and 6 weeks post discharge.
Again, there are no major notable differences between the groups.
Table 20 summarises primary care usage to 6 weeks post discharge. Again, there were no notable
differences in elements of resource use by treatment allocation. Outpatient visits were slightly more
common in the GTN group than in the placebo group, and readmissions were slightly more common in
the placebo group than in the GTN group, but the length of stay among those readmitted was higher in
the GTN group.
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TABLE 18 Resource use associated with the delivery episode by treatment allocation group
Type of hospital resources (initial episode)
Number of
observations
Treatment group (N= 1104)a
GTN (n= 541) Placebo (n= 563)
Time to placenta delivery (hours), mean (SD) 1087 1.31 (0.81) 1.28 (0.77)
Time to theatre (hours), mean (SD) 1065 0.79 (0.73) 0.75 (0.66)
Time in theatre (hours), mean (SD) 1000 0.82 (0.75) 0.82 (0.71)
Method of placenta removal, n (%) 1104
Non-manual removal of placenta
(spontaneous, controlled cord traction)
134 (24.8) 146 (25.9)
Manual removal of placenta 407 (75.2) 417 (74.1)
Blood transfusion, n (%) 1084 61 (11.4) 43 (7.8)
Length of stay (hours), mean (SD) 1014 45.46 (35.33) 42.74 (29.81)
SD, standard deviation.
a Thirteen individuals were not given drug (placebo group, n = 7; GTN group, n = 6).
TABLE 19 Secondary care resource use to 6 weeks post discharge
Outpatient resources
Number of
observations
Treatment group (N= 1104)
GTN Placebo
Number of outpatient attendances, mean (SD) 466 0.19 (0.72) 0.14 (0.47)
Readmission, n (%) 1098
Yes 16 (3.0) 29 (5.2)
No 520 (97) 533 (94.8)
Average length of stay if readmitted (number
of nights), mean (SD)
45 3.94 (13.12) 1.31 (1.85)
SD, standard deviation.
TABLE 20 Primary care resource use to 6 weeks post discharge
Type of primary care resources
Number of
observations
Treatment group, mean (SD) (N= 1104)
GTN Placebo
Number of calls 460 0.30 (1.12) 0.17 (0.46)
Number of visits 457 0.24 (0.90) 0.28 (0.93)
Number of calls made to health visitor 452 0.04 (0.37) 0.07 (0.39)
Number of health visitor visits 452 0.10 (0.52) 0.18 (0.80)
Number of visits to GP 457 0.38 (0.68) 0.49 (0.96)
Number of GP telephone consultations 446 0.18 (0.50) 0.17 (0.51)
Number of home visits by GP 436 0.03 (0.19) 0.004 (0.07)
SD, standard deviation.
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The costs associated with the initial delivery episode, from time of randomisation to time of discharge,
are summarised in Table 21 by treatment allocation. Overall, the costs were similar between groups,
with the total episode cost being slightly higher in the GTN group than in the placebo group. There were
no obvious differences between the groups in terms of the postdischarge hospital costs (Table 22) or
postdischarge primary care costs (Table 23). The estimates of postdischarge primary care costs and
outpatient costs are subject to a substantial amount of missing data, because of reliance on participant
responses to the 6-week postnatal questionnaire.
Incremental results
Table 24 summarises total costs by category and treatment allocation, and the estimated between-group
difference. It can be noted that there are no significant between-group differences in any of the major cost
categories. Directionally, there is a tendency towards slightly higher hospital episode costs in the GTN
group than in the placebo group and this difference is consistent across both the approaches used to
costing (SA1 and SA2).
TABLE 22 Postdischarge hospital costs by treatment allocation
Outpatient attendance
Number of
observations
Treatment group, mean (SD) (N= 1104)
GTN (£) Placebo (£)
Cost of outpatient appointments 466 25.65 (98.42) 18.86 (63.96)
Cost of hospital readmission 1066 52.05 (858.84) 43.32 (263.98)
SD, standard deviation.
TABLE 21 Initial hospital episode costs by treatment allocation
Hospital resource (initial episode)
Number of
observations
Treatment group, mean (SD) (N= 1104)
GTN (£) Placebo (£)
Cost of intervention 1104 3.40 (0.36) 0 (0)
Cost of monitoring by hospital 1062 98.08 (72.42) 92.51 (63.62)
Cost of surgical resource (non-manual removal
of placenta in theatre)
1095 18.15 (112.11) 26.86 (212.83)
Cost of hospital stay (for non-manual removal
of placenta, i.e. spontaneous, controlled cord
traction)
1085 154.00 (381.61) 182.76 (429.66)
Cost of manual removal of placenta 1033 1019.98 (823.80) 949.91 (710.47)
Cost of blood transfusions 1084 38.01 (105.84) 25.92 (89.17)
Total episode cost 966 1367 (734) 1317 (642)
Total episode cost (SA1) 908 1611 (970) 1534 (894)
Total episode cost (SA2) 969 1464 (841) 1381 (713)
SD, standard deviation.
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Table 25 presents the main cost outcomes alongside the principal clinical, patient-oriented and safety
outcomes, and secondary outcomes found to differ significantly between groups. Although the costs
are directionally slightly higher in the GTN group than in the placebo group, there are no significant
differences in the primary clinical, patient-oriented or safety outcomes. Furthermore, there is some
evidence of a detrimental effect of GTN on several secondary outcomes, including the need for blood
transfusions, side effects and blood pressure or heart rate.
TABLE 23 Postdischarge primary care costs by treatment allocation
Primary care resource
Number of
observations
Treatment group, mean (SD) (N= 1104)
GTN (£) Placebo (£)
Cost of calls 460 2.24 (8.19) 1.24 (3.35)
Cost of visits 457 3.52 (13.20) 4.16 (13.66)
Cost of health visitor calls 452 0.26 (2.58) 0.48 (2.72)
Cost of health visitor visits 452 1.42 (7.24) 2.56 (11.18)
Cost of GP appointments 457 13.80 (24.35) 17.69 (34.64)
Cost of GP calls 446 6.41 (17.92) 6.03 (18.49)
Cost of GP home visits 436 1.27 (8.64) 0.20 (3.00)
Total primary care cost 424 25.13 (52.29) 28.40 (58.59)
SD, standard deviation.
TABLE 24 Difference in NHS costs by category and treatment allocation
Category
Number of
observations
Treatment group, mean (SD)
(N= 1104)
Mean difference (95% CI)aGTN (£) Placebo (£)
Total episode cost 966 1366.62 (733.61) 1317.12 (642.42) 49.50 (–42.63 to 141.64)
Hospital episode cost (SA1) 908 1610.98 (970.21) 1534.46 (894.39) 76.53 (–52.62 to 205.67)
Hospital episode cost (SA2) 969 1464.35 (840.59) 1381.53 (713.59) 82.81 (–33.09 to 198.72)
Total primary care cost 424 25.13 (52.29) 28.40 (58.59) –3.28 (–13.93 to 7.38)
Cost of outpatient
appointment
466 25.65 (98.42) 18.86 (63.96) 6.79 (–10.79 to 24.37)
Cost of hospital readmission 1098 52.05 (858.84) 43.32 (263.98) 8.73 (–61.92 to 79.39)
Total NHS costb 369 1514 (1732) 1459 (779) 55.30 (–199.20 to 309.79)
SD, standard deviation.
a Cluster robust CI.
b Incorporates total episode cost, total primary care cost, cost of outpatient appointments and cost of hospital readmissions.
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Summary/discussion
The economic analysis is based on resource-use data that were collected for individual participants who
were enrolled in the trial, combined with nationally relevant unit cost data. The strengths of the analysis
include the secure randomisation, low loss to follow-up on the elements of resource use that are the
most significant cost drivers and the generalisability of the unit costs applied. A potential limitation of the
analysis is the reliance on reference costs as opposed to detailed bottom-up costing, because reference
costs can lack the precision to capture the cost impact of finer differences in patterns of resource use
between groups. To overcome this limitation we have presented more detailed data on resource use
separately from costs, and these data show very similar levels and patterns between the treatment
allocation groups. We also conducted further sensitivity analysis to assess the impact of utilising different
methods to cost the delivery episode. A further limitation of the trial was the low level of follow-up on
postdischarge resource use of primary care and hospital outpatient care. However, it can be noted from
the available data that these costs were a relatively minor component of the overall costs and did not
differ significantly between groups. In addition to the above, the economic analysis lacked an appropriate
multidimensional measure of value by which to compare the alternatives. This is primarily attributable
to the limitation of quality-adjusted life-years in this clinical context. Therefore, the analysis relied on a
cost–consequence approach, which compared the different costs and multiple consequences of the
alternative interventions without generating an incremental cost-effectiveness ratio or net benefit statistic.
However, considering the estimated costs in the context of the clinical effectiveness and safety findings,
the data provide a clear message. The use of GTN for the treatment of retained placenta is not cost-effective
compared with standard practice. Although there is a non-significant trend towards slightly higher costs in
the GTN group, there are no significant differences in the primary clinical, patient-oriented or safety outcomes.
Furthermore, directionally these primary outcomes favour placebo, and several secondary outcomes also point
towards an increased side-effect profile for GTN over placebo, a possible safety concern with respect to blood
pressure or heart rate and an increased number of blood transfusions required.
TABLE 25 Cost–consequences balance sheet
Cost/outcomes
Treatment group
Effect size 95% CIGTN Placebo
Cost of episode, mean (SD), mean difference £1367 (734) £1317 (642) +£49.50 –43 to 142
Total costs to NHS, mean (SD), mean difference £1514 (1732) £1459 (779) +£55.30 –199 to 310
Undelivered in 15 minutes, n (%), OR 505 (93.3) 518 (92.0) 1.01 0.98 to 1.04
Patient satisfaction (would recommend to a friend), n (%), OR
Predischarge 288/382 (75.4) 303/388 (78.1) 0.87 0.62 to 1.22
6 weeks 166/221 (75.1) 178/238 (74.8) 1.02 0.66 to 1.56
Palpitations/heart racing, n (%), OR
Predischarge 36/368 (9.8) 15/375 (4.0) 2.60** 1.40 to 4.84
6 weeks 14/200 (7.0) 10/225 (4.4) 1.62 0.70 to 3.73
Blood loss (ml), n (%), OR
Blood loss (ml)
< 500 238/537 (44.3) 249/560 (44.5)
500–1000 180/537 (33.5) 224/560 (40.0)
> 1000 119/537 (22.2) 87/560 (15.5) 1.14 0.88 to 1.48
Blood transfusion 61/533 (11.4) 43/551 (7.8) 1.53* 1.04 to 2.25
Fall in blood pressure/heart rate 323/531 (60.8) 131/544 (24.1) 4.90*** 3.73 to 6.42
*p < 0.05, **p < 0.01, ***p < 0.001.
SD, standard deviation.
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Chapter 7 Discussion and conclusions
Aim and overview
Non-surgical management options for retained placenta are limited and it is recognised that further
research is required to examine medical management strategies for retained placenta.1,8 Current
management of manual removal of retained placenta poses a risk of bleeding and infection, and a new
safer medical management that is more acceptable to women is urgently required.
Our large, pragmatic, randomised, double-blind trial was designed to determine the effectiveness of GTN
spray as an alternative management for removal of retained placenta. It included an internal pilot study
and the substantive trial measured four primary outcomes: clinical, safety, patient sided and economic.
We also collected data for a number of secondary outcomes.
Summary of findings
This large, multicentre RCT demonstrated no difference between the GTN and placebo groups for the
clinical outcome of the placenta remaining undelivered or the need for manual removal of placenta within
15 minutes of the study drug being administered. For the primary safety outcome, although numerically
there appeared to be a greater number of bleeds of < 1000 ml in the GTN group, when compared with
the placebo group this difference was not statistically significant. The only patient-sided difference noted
was that the group that received the intervention of GTN reported an increase in the side effects of
palpitations and tachycardia pre discharge. These side effects are consistent with previously reported side
effects for GTN spray.
The main findings of the secondary outcomes were noted to be a decrease of 15 mmHg in systolic or
diastolic blood pressure and/or increase in heart rate of > 20 b.p.m. noted for those in the GTN group.
In addition, a greater number of participants in the GTN group also required a blood transfusion between
the time of delivery and discharge from hospital.
The health economic analysis demonstrated no notable differences in elements of resource use associated
with the hospital stay. Following discharge from hospital, there were no differences noted in the use of
primary and secondary care services, but outpatient visits were marginally more frequent in the GTN group
than in the placebo group. Readmission to hospital was slightly more common in the placebo group than
in the GTN group, although the length of stay was noted to be higher in the GTN group than in the
placebo group. The overall cost of the initial hospital stay was noted to be very similar for the two groups,
with the GTN group being fractionally higher.
Strengths and limitations of the trial
We believe that the GOT-IT trial is the largest multicentre, randomised double-blind trial that has been
undertaken to determine the effectiveness of GTN for retained placenta. The selection of a variety of hospitals
has allowed us to produce results that are robust, reliable and generalisable. Furthermore, all sites received
onsite monitoring visits from trained clinical trial monitors, which strengthened the validity of the data.
The group-sequential design of the trial provided the DMC opportunities for interim data evaluations. This
approach allowed the maximum number of participants to be recruited into the trial, while also providing
the opportunity for the trial to be stopped early if there had been either an overwhelming evidence of
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benefit or signs of futility. Hence, the use of a group-sequential approach confirmed that we were required
to randomise the maximum number of participants to the trial to achieve the definitive result for our study.
The inclusion of the internal pilot study was beneficial in obtaining the views of both women and staff to
refine the consent pathway and optimise recruitment strategies for the substantive trial.
The trial completed the recruitment phase 2 months ahead of the projected recruitment completion date.
As the primary clinical outcome was obtained within 15 minutes of study drug administration, we achieved
100% completeness. The majority of women who were invited to participate in the trial were willing to do
so as they believed that the study medication (if they received the GTN intervention) could potentially
prevent them from having a manual removal of their placenta. Thus, we are confident that our cohort
accurately represented the demographic of women who sustain retained placenta.
We experienced problems in the early phase of recruitment with one component of the inclusion criteria.
The term ‘haemodynamically stable’ was originally defined as a systolic blood pressure level of > 100 mmHg
and a heart rate of < 110 b.p.m. However, in a minority of cases, clinicians were interpreting women as
being ‘haemodynamically stable’ if their systolic blood pressure and heart rate were just outside these
parameters. To clarify this, we redefined the definition of ‘haemodynamically stable’ in the protocol and
submitted it as a substantial amendment to gain required approvals. The redefined definition read as follows.
Haemodynamically stable (must satisfy all three definitions):
1. haemodynamically stable
2. a heart rate of ≤ 119 b.p.m.
3. a systolic blood pressure level of > 100 mmHg.
This redefinition prevented any further protocol violations.
We anticipated that recruitment to the GOT-IT trial might be very challenging. The unpredictable nature of
retained placenta meant that it could occur at any point within a 24-hour period. Successful delivery of this
trial would therefore depend on clinicians (and not research staff) identifying, consenting and randomising
women to trial entry alongside providing them with clinical care for an obstetric emergency. Very few
of the trial sites had any experience of delivering a CTIMP in a busy labour ward setting, which posed
logistical challenges particularly around safe storage of the investigational medicinal product in the labour
ward setting. Finally, the good clinical practice requirements for such trials meant that all research and
clinical staff were required to have either full good clinical practice training or study-specific training (with
sponsor-approved good clinical practice training embedded within it) prior to consenting a participant into
the trial. Of these, we believed that the last was likely to be the biggest barrier to clinician involvement
in the trial. Working closely with our sponsor, we therefore developed study-specific training, including
sponsor-approved good clinical practice training, to facilitate trial delivery. We believe that this was
instrumental in the success of recruitment to this trial as this study-specific training allowed clinicians and
clinical midwives who were not fully good clinical practice trained to consent eligible participants to the trial.
To further aid recruitment in an intrapartum setting, we chose to randomise trial participants using a ‘next
off the shelf’ system rather than by a telephone or computing randomisation system. We were concerned
that use of a telephone or computer system to randomise a participant would increase the time until the
study drug was administered. We were therefore concerned that any possible delay in administering study
medication, in the context of the life-threatening medical emergency of retained placenta, would influence
the clinical teams’ decision to enrol participants and would subsequently affect study recruitment. Thus,
the trial medication was signed out of pharmacy via a pharmacy accountability log and signed in to the
labour ward via a labour ward accountability log. Once the study medication was on the labour ward,
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it was stored in a specific locked area subject to regular temperature monitoring. Locating the study drug
on the labour ward allowed it to be administered rapidly with no delay. Use of the drug was recorded on
a labour ward dispensing log, and return of the used vial to pharmacy was captured on the labour ward
accountability log. The used vial was then signed back into pharmacy via the pharmacy accountability log
before undergoing destruction as per local policy.
The main weakness of our trial was our underestimation of the anticipated return of the 6-week
questionnaire sent out from the trial office. Despite sending reminders, the return rate of 6-week
questionnaires for both the GTN group and the placebo group of the trial was initially only 20%. However,
following the implementation of the thank-you cards, as a result of recommendations from the qualitative
research, we saw the overall return rate increase to 43%. We believe that this increase in return rate was
attributable to thanking the women for their participation in the trial by sending the cards. Nevertheless,
an overall return rate of 43% was lower than anticipated and we attribute this to women finding it
difficult to have the time to complete and return questionnaires via the post when they are looking after
a young infant. We are aware that this low return rate may have some influence on the results of the
economic evaluation. However, as the return rates were similar for both the GTN group and the placebo
group, we believe that any similarities or minor differences noted between the two groups would have
remained similar should the return rates have been higher.
Conclusions
l No benefit was observed from use of GTN as the number of placentae that remained undelivered or
required manual removal of placenta within 15 minutes was similar in both the GTN group and the
placebo group (primary clinical outcome).
l Measured blood loss was comparable for both groups (primary safety outcome).
l Self-reported palpitations were reported more commonly prior to hospital discharge in participants who
had received GTN compared with placebo. There were no other differences in side effect or satisfaction
profile between groups (primary patient-sided outcome).
l The health economic evaluation did not report any significant differences in the use of health resources
between the two groups during the in-hospital stay, or the period from discharge to 6 weeks following
hospital discharge (primary economic outcome).
l Qualitative research with participants and staff helps to inform the recruitment and consent pathway,
and inform study design for trials recruiting in emergency settings.
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